Study Title: A Phase 2, Open -Label, Multi -Center Study to Evaluate the Safety, 
Pharmacokinetics and Pharmacodynamics of Lixivaptan in Subjects With Autosomal 
Dominant Polycystic Kidney Disease  
ClinicalTrials.gov ID: [STUDY_ID_REMOVED]  
Clinical  Study Protoc ol Version 5.0, dated March 21, 2019  
Summary of Changes in the Conduct of the Study (from Section 9.8.1 of the Clinical S tudy 
Report, dated September 22, 2020  
Clinical Study Protocol Version 5.0, dated March 21, 2019, Summary of Changes 
Clinical Study Protocol Version 4.0, dated January 9, 2019, Summary of Changes 
 
 
CLINICAL STUDY PROTOCOL  
 
A Phase 2, Open -Label, Multi -Center Study to Evaluate the Safety, 
Pharmacokinetics and Pharmacodynamics of Lixivaptan in Subject s with 
Autosomal Dominant Polycystic Kidney Disease  
 
Protocol  Number : PA-102 
IND Number : 136,419  
 
Sponsor:  Palladio Biosciences , Inc.  
12 Penns Trail  
Unit A  
Newtown, PA 18940 
Sponsor Contact: Elaine Richardson  
Vice President, Clinical Operations  
Palladio Biosciences, Inc. 
12 Penns Trail, Unit A Newtown, PA 18940 ERichardson@palladiobio.com  
  
Medical Monitor:  Andrew Lowy, MD, FRACP  
Medical Director , IQVIA  
Direct: (984) 201-6550 (including urgent medical issues) Mobile: (310) 431-7666 Fax: +1 (520) 829-9405 Email: Andrew.Lowy@quintiles.com   
 IQVIA 24/7 Medical Emergency Contact Center (MECC):  
(973) 659-6677;  (512) 652-0191 (back-up) 
 
Version of Protocol:  5   
Date of Protocol:  March  21, 2019   
 
21-Mar-2019  Confidential Information  Version 5  
 
 
CONFIDENTIAL  
All financial and nonfinancial support for this study will be provided by Palladio 
Biosciences .  The concepts and information contained in this document or generated during 
the study are considered proprietary and may not be disclosed in whole or in part without the expressed, written consent of Palladio Biosciences .  The study will be conducted according to 
the International Council for Harmonisation (ICH) harmonized tripartite guideline E6 (R1): 
Good Clinical Practice (GCP).  
 
  
 
   
 
   
 
   
 
Palladio Biosciences  PA-102 Page 3 of 66 
 
21-Mar-2019  Confidential Information  Version 5  Protocol Approval  - Sponsor Signat ure 
Protocol Title  A Phase 2, Open -Label, Multi- Center Study to Evaluate the Safety, 
Pharmacokinetics and Pharmacodynamics of Lixivaptan in Subjects 
with Autosomal Dominant Polycystic Kidney Disease  
Protocol Number PA-102 
Protocol Version  5 
Protocol Date March 21, 2019 
 
Protocol accepted and approved by: Neil H. Shusterman, M.D. 
Chief Medical Officer  
Palladio Biosciences, Inc. 12 Penns Trail, Unit A Newtown, PA 18940    
 
        March 21, 2019 
Signature   Date  
 

Palladio Biosciences  PA-102 Page 4 of 66 
 
21-Mar-2019  Confidential Information  Version 5  Declaration of Investigator  
I have read and underst ood all sections of the protocol titled “A Phase 2, Open- Label, 
Multi- Center Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of 
Lixivaptan in Subjects with Autosomal Dominant Polycystic Kidney Disease ” and the 
accompanying current version of the Investigator B rochure  (IB) . 
I agree to supervise all aspects  of the protocol and to conduct the clinical investigation in 
accordance with the protocol, the ICH harmonized tripartite guideline E6  (R1): GCP , and all 
applicable government regulations.  I will not make changes to the protocol before consulting 
with Palladio Biosciences  or implement protocol changes without Institutional Review Board  
(IRB) approval except to eliminate an immediate risk to subject s.  I agree to administer study 
treatment only to subjects under my personal supervision or the supervision of a Sub-Investigator. 
I will not supply the investigational drug to any person not authorized to receive it.  
Confidentiality will be protected.  Subject  identity will not be disclosed to third parties or 
appear in any study reports or publications. 
I will not disclose information regarding this clinical investigation or publish results of the 
investigation without authorization from Palladio Biosciences . 
 
   
Signature of Investigator   Date  
   
Printed Name of Investigator    
 
Palladio Biosciences  PA-102 Page 5 of 66 
 
21-Mar-2019  Confidenti al Information  Version 5  TABLE OF CONTENTS  
TABLE OF CONTENTS  ...........................................................................................................5  
LIST OF TABLES  .....................................................................................................................8  
PROTOCOL SYNOPSIS  ...........................................................................................................9  
LIST OF ABBREVIATION S ..................................................................................................12  
1 INTRODUCTION  ............................................................................................................15  
1.1 Background .............................................................................................................15  
1.2 Overview of ADPKD  ..............................................................................................15  
1.3 Overview of Available Therapies for ADPKD  .......................................................16  
1.4 Rationale for Lixivaptan Therapy for ADPKD  .......................................................16  
1.5 Summary of Nonclinical Studies  ............................................................................18  
1.6 Summary of Clinical Studies  ..................................................................................18  
1.7 Study Rationale .......................................................................................................19  
1.8 Dose Rationale  ........................................................................................................19  
2 STUDY OBJECTIVES AND ENDPOINTS  ....................................................................20  
2.1 Study Objectives  .....................................................................................................20  
2.1.1  Primary Objectives  ..................................................................................20  
2.1.2  Secondary Objectives  ..............................................................................20  
2.2 Study En dpoints ......................................................................................................20  
2.2.1  Primary Endpoints ...................................................................................20  
2.2.2  Secondary Endpoints ...............................................................................21  
3 INVESTIGATIONAL PLAN  ...........................................................................................22  
3.1 Study Design  ...........................................................................................................22  
3.1.1  Rationale of Study Design .......................................................................23  
4 SUBJECT SELECTION AND WITHDRAWAL CRITERI A .........................................25  
4.1 Selection of Study Population .................................................................................25  
4.1.1  Inclusion Criteria  .....................................................................................25  
4.1.2  Exclusion Criteria  ....................................................................................27  
4.2 Withdrawal of Subjects from the Study ..................................................................29  
4.2.1  Reasons for Withdrawal/Discontinuation ................................................29  
4.2.2  Handling of Withdrawals  .........................................................................30  
4.2.3  Replacements  ...........................................................................................31  
Palladio Biosciences  PA-102 Page 6 of 66 
 
21-Mar-2019  Confidenti al Information  Version 5  5 STUDY TREATMENTS  ..................................................................................................32  
5.1 Method of Assigning Subjects to Treatment Groups ..............................................32  
5.2 Blinding and Randomization ..................................................................................32  
5.3 Treatments Administered  ........................................................................................32  
5.4 Identity of Investigational Product ..........................................................................33  
5.5 Management of Clinical Supplies  ...........................................................................33  
5.5.1  Study Drug Packaging and Storage .........................................................33  
5.5.2  Test Article Accountability  ......................................................................34  
5.6 Overdose Management  ...........................................................................................34  
5.6.1  Treatment of Overdose ............................................................................34  
5.7 Treatment Compliance  ............................................................................................34  
5.7.1  Study Dosing Diary  .................................................................................34  
5.8 Prior and Concomitant Therapy  ..............................................................................35  
5.8.1  Permitted Therapy  ....................................................................................35  
5.8.2  Prohibited Therapy  ..................................................................................36  
5.9 Diet, Fluid, and Activity Control ............................................................................37  
6 STUDY ASSESSMENTS AN D PROCEDURES  ............................................................39  
6.1 Safety and Tolerability Assessments  .......................................................................39  
6.1.1  Body Height, Weight, and BMI ...............................................................39  
6.1.2  Physical Examinations and Medical History  ...........................................39  
6.1.3  Vital Sign Measurements  .........................................................................39  
6.1.4  12-Lead Electrocardiograms  ....................................................................40  
6.1.5  Clinical Laboratory Tests  .........................................................................40  
6.1.6  MRI Assessment  ......................................................................................41  
6.1.7  Urine Osmolality and Specific Gravity  ...................................................42  
6.1.8  Questionnaire for Tolerability  ..................................................................42  
6.1.9  Adverse Events  ........................................................................................43  
6.2 Laboratory Analyses  ...............................................................................................46  
6.3 Pregnancy  ................................................................................................................46  
7 STATISTICAL AND ANAL YTICAL PLAN  ...................................................................47  
7.1 Pharmacokinetic Parameters  ...................................................................................47  
7.2 Pharmacodynamic Parameters  ................................................................................48  
7.3 Safety Variables  ......................................................................................................48  
7.4 Sample Size Calculations  ................................................................ ........................49  
Palladio Biosciences  PA-102 Page 7 of 66 
 
21-Mar-2019  Confidenti al Information  Version 5  7.5 Analysis Sets  ...........................................................................................................49  
7.6 Description of Subgroups to be Analyzed ..............................................................49  
7.7 Statistical Analysis Methodology  ...........................................................................50  
7.7.1  Pharmacokinetic Analysis  ........................................................................50  
7.7.2  Pharmacodynamic Analyses  ....................................................................50  
7.7.3  Safety Analyses  ........................................................................................51  
7.7.4  Other Analyses  .........................................................................................52  
7.8 Data Quality Assurance ...........................................................................................52  
7.8.1  Data Management  ....................................................................................53  
8 ETHICS  ............................................................................................................................54  
8.1 Institutional Review Board  .....................................................................................54  
8.2 Ethical Conduct of the Study ..................................................................................54  
8.3 Subject Information and Consent ............................................................................54  
9 INVESTIGATOR ’S OBLIG ATIONS  ..............................................................................55  
9.1 Confidentiality  ........................................................................................................55  
9.2 Financial Disclosure and Obligations .....................................................................55  
9.3 Investigator Documentation ....................................................................................55  
9.4 Study Conduct .........................................................................................................56  
9.5 Adherence to Protocol .............................................................................................56  
9.6 Adverse Events and Study Report Requirements ...................................................56  
9.7 Investigator’ s Final Report  .....................................................................................56  
9.8 Records Retention ...................................................................................................56  
9.9 Publications .............................................................................................................57  
10 STUDY MANAGEMENT  ...............................................................................................58  
10.1  Monitoring ..............................................................................................................58  
10.1.1  Monitoring of the Study ...........................................................................58  
10.1.2  Inspection of Records ..............................................................................58  
10.2  Manag ement of Protocol Amendments and Deviations ..........................................58  
10.2.1  Modification of the Protocol ....................................................................58  
10.2.2  Protocol Deviations ..................................................................................58  
10.3  Study T ermination  ...................................................................................................59  
10.4  Final Report ............................................................................................................59  
11 REFERENCE LIST  ..........................................................................................................60  
Palladio Biosciences  PA-102 Page 8 of 66 
 
21-Mar-2019  Confidenti al Information  Version 5  12 APPENDICES  ..................................................................................................................62  
12.1  Appendix 1: Chronic Kidney Disease Classification Criteria  ................................62  
12.2  Appendix 2: Schedule of Assessments ...................................................................62  
12.3  Appendix 3: Assessment Windows  .........................................................................66  
 
LIST OF TABLES  
Table 3 -1 Chronic Kidney Disease Classification Summary  .......................................... 23  
Table 5 -1 Study Cohorts and Lixivaptan Dose Levels .................................................... 32  
Table 5 -2 Investigational Product ................................................................................... 33  
Table 6 -1 Clinical Laboratory Parameters  ...................................................................... 41  
Table 6 -2 Guideline for Assessment of Adverse Event Causality ................................... 45  
Table 7 -1 Probability of Not Observing an Adverse Event for Various True Incidence 
Rates  ................................................................................................................ 49  
Table 12 -1 Schedule of Assessments  ................................................................................ 63  
Table 12 -2 Assessment Windows ...................................................................................... 66  
 
Palladio Biosciences  PA-102 Page 9 of 66 
 
21-Mar-2019  Confidenti al Information  Version 5  PROTOCOL SYNOPSIS  
Protocol Number:  PA-102 
Protocol Title:  A Phase 2, Open -Label, Multi -Center Study to Evaluate the Safety, 
Pharmacokinetics and Pharmacodynamics of Lixivaptan in Subjects with Autosomal 
Dominant Polycystic Kidney Disease  
Sponsor:  Palladio Biosciences  
12 Penns Trail  
Unit A  
Newtown, PA 18940  
Study Phase:  Phase 2  
Study Sites:  Approximately 15 sites  
Indication:  Autosomal Dominant Polycystic Kidney Disease  
Rationale:  Therapeutic interventions aimed at counterbalancing the effect of vasopressin may be effective in delaying disease progression in autosomal dominant polycystic kidney disease (ADPKD).  
Objectives:  The primary objectives of this study are:  
• To characterize the safety and tolerability of lixivaptan following multiple doses in ADPKD subjects with relatively preserved kidney function (chronic kidney disease CKD1 and CKD2) and moderately impaired renal functi on 
(CKD3).  
• To characterize the PK profile of lixivaptan and its major metabolites (WAY -
141624, WAY -138451, and WAY -138758) following multiple doses of 
lixivaptan in ADPKD subjects with relatively preserved kidney function (CKD1 and CKD2) and moderately impaired renal function (CKD3). 
The secondary objectives of this study are:  
• To characterize the effect of lixivaptan on urine osmolality over a 24 -hour 
period following multiple doses of lixivaptan in ADPKD subjects.  
• To characterize the time course of the hem odynamic effect of lixivaptan on 
urine output, total kidney volume, liver volume, circulating  vasopressin, and 
serum creatinine in ADPKD subjects. 
Subject Population:  The subjects will be m ale or female, between 18 and 65 years of age (inclusive) at 
the time of Screening, with a body mass index (BMI) between 18 and 35 kg/m2 
(inclusive) at the time of Screening.   The subjects will have an estimated glomerular 
filtration rate (eGFR) ≥ 60 mL/min/1.73 m2 (Cohort 1  and 3 ), or eG FR ≥  30 to <  60 
mL/min/1.73 m2 (Cohort 2  and 4 ), with eGFR calculated by the Chronic Kidney 
Disease Epidemiology Collaboration ( CKD -EPI) equation.   Subject s will have been  
diagnosed with ADPKD based on  modified Ravine criteria . 
Study Design:  This is a Phase 2, open -label, parallel -group, multiple dose study designed to 
evaluate the PK, PD, safety, and tolerability of multiple BID doses of 50 and 200 mg lixivaptan in ADPKD subjects with chronic kidney disease in stages CKD1, CKD2 or CKD3.   
Palladio Biosciences  PA-102 Page 10 of 66 
 
21-Mar-2019  Confidenti al Information  Version 5  Estimated Study 
Duration:  Screening Duration: 42 days (Day - 44 through Day -3)  
Confinement Period: Subjects will be confined from Check in (Day -2 or Day -1) 
until Day 2 in the morning. Subjects will be confined from Day 6 in the afternoon through Day 8 in the morning. 
Outpatient: Subjects will return to the clinical research unit (CRU)  on an outpatient 
basis on Day 4 in the morning and Day 6 in the morning  for a trough PK assessment . 
End of Study Visit: Subjects will return on Day 35 (±2) for end of study assessment.  
Total Study Duration : Up to 80 days 
Study Drug, Dosage, and Route of Administration: The Sponsor (Palladio Biosciences, Inc.) will provide adequate supplies of lixivaptan 50 mg capsules for use during the study.  
Enrolled subjects will be assigned according to CKD classification to take one of 2 
lixivaptan oral dose regimens for 7 days  as shown below .  Each dose regimen 
includes morning (AM) and evening (PM) oral administration of lixivaptan.  
Cohort  CKD stage  Dose  N 
1 CKD1 or CKD2  200 mg BID  8 subjects  
2 CKD3  200 mg BID  8 subjects  
3 CKD1 or CKD2  50 mg BID  8 subjects  
4 CKD3  50 mg BID  8 subjects  
 Doses of lixivaptan will be administered both at the CRU and at home.   
Study Assessments:  Pharmacokinetic: The following PK parameters will be calculated using 
noncompartmental methods, whenever possible, based on lixivaptan and lixivaptan 
metabolite concentrations:  the maximum observed plasma drug concentration (C
max), the time to reach maximum plasma concentration (t max), the area under the 
concentration -time curve (AUC) from time 0 until the last quantifiable concentration 
(AUC0-t), AUC from time 0 until 14 hours postdose (AUC 0-14), AUC extrapolated to 
infinity (AUC 0-inf), the apparent terminal elimination rate constant (λz), the terminal 
elimination phase half -life (t 1/2), total body clearance (CL/F), and the volume of 
distrib ution (Vz/F).  
Pharmacodynamic:  The pharmacodynamic (PD) analysis will include assessments 
of urine osmolality and urine output, total kidney volume, liver volume, plasma  
copeptin and serum creatinine.  
Safety: The safety analysis will include clinical labor atory findings (hematology, 
clinical chemistry, and urinalysis), 12 -lead electrocardiograms (ECGs), vital signs, 
physical examination findings, assessments of adverse events (AE) and the questionnaire of tolerability.  
Sample Size:  Approximately 32 subjects (8 subjects in CKD1/2 and 8 subjects in CKD3 per dose level ). 
Palladio Biosciences  PA-102 Page 11 of 66 
 
21-Mar-2019  Confidenti al Information  Version 5  Statistical Methods: Pharmacokinetic:  Lixivaptan and lixivaptan metabolite  (WAY -141624, WAY -
138451, and WAY -138758)  plasma concentrations will be tabulated and 
summarized using descriptive statistics (including sample size, arithmetic and 
geometric mean, standard deviation [ SD], coefficient of variation [ CV% ], median, 
minimum, and maximum) for each Cohort .  The PK parameters for lixivaptan and 
lixivaptan metabolite s will be summarized for each Cohort. 
Plasma concentration data for lixivaptan and  lixivaptan metabolites  will also be 
displayed graphically on linear and semi -logarithmic scales.  The following plots 
will be p resented for the concentration -time data:  
• Individual subject plasma concentration profile versus time, stratified by Cohort . 
• Arithmetic -mean concentration (±SD) versus time, stratified by Cohort . 
Pharmacodynamic: The change from baseline in urine osmolalit y, serum 
creatinine, plasma copeptin , total kidney volume ( TKV) and liver volume ( LV) after 
multiple doses of lixivaptan will be summarized by renal function group (CDK1/2 
and CDK3), and at each scheduled time point using descriptive statistics (n, mean, 
SD, median, minimum, and maximum).  
Safety: Safety assessments, including clinical laboratory findings (hematology, 
clinical chemistry, and urinalysis), 12 -lead electrocardiograms (ECGs), vital signs, 
physical examination findings, assessments of adverse events (AE s) and the 
questionnaire of tolerability will be analyzed descriptively.  
Date of Protocol:  March  21, 2019  
 
 
Palladio Biosciences  PA-102 Page 12 of 66 
 
21-Mar-2019  Confidenti al Information  Version 5  LIST OF ABBREVIATIONS 
Abbreviation Definition  
ADPKD  autosomal dominant polycystic kidney disease 
AE adverse event  
ALT alanine aminotransferase  
AST  aspartate aminotransferase 
AUC  area under the curve  
AUC 0-inf area under the concentration -time curve extrapolated to infinity  
AUC 0-t area under the concentration -time curve from time 0 until the last 
quantifiable concentration 
BID twice per day  
BLQ  below the limit of quantitation  
BMI  body mass index 
BUN  blood urea nitrogen 
cAMP  cyclic adenosine 3’,5’-monophosphate 
CDER  Center for Drug Evaluation and Research  
CDISC  Clinical Data Interchange Standards Consortium  
CFR  Code of Federal Regulations  
CKD chronic kidney disease 
CL/F  total body clearance  
Cmax maximum observed plasma drug concentration  
CRU  Clinical Research Unit  
CS clinically significant  
CT computerized tomography 
CV coefficient of variation  
ECG  electrocardiogram  
eCRF  electronic Case Report Form  
EDC  electronic data capture  
eGFR  estimated glomerular filtration rate  
EOS  end of study 
ET early termination  
FDA  Food and Drug Administration  
FSH follicle -stimulating hormone 
GCP  Good Clinical Practice  
HBsAg  hepatitis B surface antigen  
hCG human chorionic gonadotropin 
Palladio Biosciences  PA-102 Page 13 of 66 
 
21-Mar-2019  Confidenti al Information  Version 5  Abbreviation Definition  
HIV human immunodeficiency virus  
I/E inclusion/exclusion  
IB Investigator Brochure 
ICF Informed Consent Form 
ICH International Council for Harmonisation  
IND Investigational New Drug  
IRB Institutional Review Board  
LV liver volume 
MedDRA  Medical Dictionary for Regulatory Activities  
MRI  magnetic resonance imaging  
n number of non-missing observations 
N number of subjects  
NCS  not clinically significant  
OTC  over-the-counter 
PD pharmacodynamic  
PK pharmacokinetic  
PKD  polycystic kidney disease  
PT preferred term  
QTcF  QT interval corrected for heart rate according to Fridericia’ s formula  
REMS  Risk Evaluation and Mitigation Strategy  
SAE  serious adverse event  
SAP Statistical Analysis Plan  
SAS Statistical Analysis S ystem  
Scr serum creatinine  
SD standard deviation 
SOC  system organ class  
Sosm serum osmolality  
t1/2 terminal elimination phase half -life 
TEAE treatment -emergent adverse event  
TKV  total kidney volume 
tmax time to reach maximum plasma concentration  
ULN  upper limit of normal  
Uosm urine osmolality  
US United States  
Vz/F  volume of distribution 
Palladio Biosciences  PA-102 Page 14 of 66 
 
21-Mar-2019  Confidenti al Information  Version 5  Abbreviation Definition  
Λz apparent terminal elimination rate constant  
Palladio Biosciences  PA-102 Page 15 of 66 
 
21-Mar-2019  Confidenti al Information  Version 5  1 INTRODUCTION 
1.1 Background  
Lixivaptan (also known as VPA-985, BIIB030, and CL 347,985) is a potent, non-peptide 
selective antagonist for the vasopressin V 2 receptor, which is expressed primarily in the 
collecting duct of the nephron.1  Lixivaptan antagonizes the effects of vasopressin that are 
mediated by the V 2 receptor, resulting in the pharmacologic effect of increased free water 
excretion, thus decreasing urine osmolality (U osm), increasing urine flow and increasing 
serum osmolality (S osm) as well as restoring normal levels of intracellular cyclic adenosine 
3’,5’-monophosphate ( cAMP ).2   
The Sponsor ( Palladio Biosciences, Inc. ) is currently developing lixivaptan for the treatment 
of Autosomal Dominant Polycystic Kidney Disease (ADPKD).  Lixivaptan had previously 
been under development for the treatment of symptomatic hypervolemic and euvolemic 
hyponatremia associated with heart failure (HF)  and syndrome of inappropriate anti- diuretic 
hormone secretion (SIADH).   
Additional background information for l ixivaptan  can be found in the Investigator’s 
Brochure . 
1.2 Overview of ADPKD 
Definition  
Autosomal dominant polycystic kidney disease (ADPKD) is a hereditary kidney disorder 
characterized by cyst formation and progressive enlargement in the kidney, liver and other organs.  It results from loss -of-function mutations in either of 2 genes ( pkd1  and pkd2), 
encoding transmembrane polycystin proteins PC1 (polycystin 1) and PC2 (polycystin 2), respectively.  
In the kidney, loss-of-function mutations in pkd1 or pkd2 disrupt the normal differentiated phenotype of the renal tubular epithelium.  The se mutations  lead to elevated intracellular 
levels of  cAMP, which in turn results in increased cellular division and apoptosis, a loss of 
mitotic polarity, a disruption of the normal differentiated cellular phenotype, cyst formation, and fluid secretion into renal cysts.
3 The progressive development and growth of numerous 
bilateral renal cysts  results in fibrosis, renal architectural derangement  and destruction of 
normal kidney tissue .  Disease progression is accompanied by urine concentration defects, 
hypertension, acute and chronic pain, kidney stones, haematuria, cyst and urinary tract infections, and, most importantly, renal function loss and kidney failure.
3,4 
The most frequent extrarenal manifestation of ADPKD is polycystic liver disease, which is typically associated with increased renal volume, older age, and female sex .  Liver cysts are 
usually asymptomatic, and the liver function is normal.  However, in some cases the 
increased liver volume may lead to hepatomegaly as a result of the continuous cyst 
enlargement.
5 This may cause symptoms of extrinsic compression, such as abdominal pain, 
early satiety, and obstruction of the hepatic veins or bile duct; and liver cyst infections cause 
Palladio Biosciences  PA-102 Page 16 of 66 
 
21-Mar-2019  Confidenti al Information  Version 5  fever, right upper abdominal pain, and possible elevated CA19.9 and alkaline phosphatase 
(ALP) levels.  
Epithelial cells derived from human ADPKD cysts generate elevated intracellular levels of 
cAMP in response to vasopressin, which in turn promotes cell proliferation and electrolyte secretion.
6  Increased fluid secretion into cysts is due to vasopressin-induced transepithelial 
secreti on of chloride.  Patients with ADPKD also have elevated plasma concentrations of 
vasopressin or an exaggerated response of vasopressin to sodium challenge as compared to normal individuals.
7  Pharmacological interventions aimed at inhibiting vasopressin 
signalling are therefore expected to restore normal cellular function and provide a disease -
modifying effect on disease progression in ADPKD.  
1.3 Overview of  Available Therapies for ADPKD 
In April 2018, the vasopressin V 2 receptor antagonist tolvaptan (JYNARQUE®) was 
approved in the US to slow kidney function decline in adults at risk of rapidly progressing ADPKD.  However, because of the risk of serious liver injury, Jynarque is only available through a restricted distribution program under a Risk Evaluation and Mitigation Strategy (REMS).  
The European Medicines Agency ( EMA ) granted a positive opinion for the vasopressin V
2 
receptor antagonist tolv aptan ( JINARC®) in 2015 to slow the progression of cyst 
development and failing kidney function in adult patients with ADPKD with normal to 
moderately -reduced kidney function who have rapidly progressing ADPKD.  The Committee 
for Medicinal Products for Hum an Use ( CHMP ) recommended additional monitoring of the 
risk of liver damage with tolvaptan.  Similar approvals were granted in Japan, Canada, and Australia/New Zealand.  The US Food and Drug Administration ( FDA ) did not grant 
approval to tolvaptan for the treatment of ADPKD primarily due to concerns regarding liver safety.  
1.4 
Rationale for Lixivaptan Therapy for ADPKD  
Given that elevated renal cAMP plays a pivotal role in the complex phenotypical 
manifestation of AD PKD ,6 and that vasopressin is the principal agonist pathway leading to 
the formation of cAMP in kidney tubule cells, it has been suggested that therapeutic 
interventions aimed at counterbalancing t he effect of vasopressin and/or normalizing 
intracellular levels of cAMP may be effective in delaying disease progression in ADPKD.7  
This hypothesis was confirmed by genetic experiments in mutated rats with no circulating serum vasopressin (Brattleboro rats) .  When these rats were crossed with rats harboring a 
PKD mutation, their offspring did not develop cysts,
8 thus demonstrating that an intact 
vasopressin signaling  pathway is a necessary requirement for the development of cystic 
disease.  In addition, vasopressin receptor antagonists, including mozavaptan9  and 
tolvaptan10, have proved efficacious in normalizing renal cAMP levels and correcting disease 
manifestations in preclinical rodent models of ADPKD .  In ADPKD patients, elevated levels 
of circulating copeptin, a marker for serum vasopressin concentration, are associated with faster disease progression.
11 
Palladio Biosciences  PA-102 Page 17 of 66 
 
21-Mar-2019  Confidenti al Information  Version 5  Further, definitive evidence in favor  of the utility of vasopressin antagonism as a therapeutic 
approach for ADPKD is derived from tolvaptan, like lixivaptan a non- peptide vasopressin V 2 
receptor antagonist in the drug class of vaptans.  In Europe, tolvaptan (JINARC®) is 
approved to slow the progression of cyst development and renal insufficiency of ADPKD in 
adults with CKD stage 1 to 3 at initiation of treatment with evidence of rapidly progressing 
disease.  Approval was granted based on the findings from the pivotal phase 3 trial TEMPO 3:4, the largest placebo-controlled Phase 3 study ever conducted in ADPKD.  The trial 
randomized 1445 patients with ADPKD with a total kidney volume of ≥  750 mL and an 
estimated creatinine clearance of ≥  60 mL/min to tolvaptan or placebo.  Ove r a 3-year period, 
tolvaptan delayed the worsening of kidney function, a therapeutic effect that was 
subsequently found to have disease-modifying properties, and slowed the progression of 
kidney enlargement .
12,13  Importantly, the TEMPO 3:4 trial also demonstrated that, in patients 
receiving tolvaptan, there was a strong, inverse relationship between the magnitude of the 
aquaretic response, measured by decrease in urinary osmolality, and the loss of renal function 
during the study.14  Because complete vasopressin suppression is ensured if urinary 
osmolality is lowered to <  300 mOsm/kg, these findings strongly suggest that achieving 
urinary osmolality reduction below this target threshold can be considered a predictive biomarker of clinical efficacy of vasopressin antagonists for the treatment of ADPKD .
14 
More recently, the results of REPRISE, a second pivotal P hase 3 study with tolvaptan for the 
treatment of ADPKD, were published.15  This trial randomized 1370 patients with later stage 
ADPKD, which was defined as having a baseline estimated eGFR of  < 65 mL/min for 
patients in the 18-55 age group or < 45 mL/min for patien ts in the 56-65 age group, to 
tolvaptan or placebo.  Over a 12 -month period, tolvaptan delayed the eGFR decline, a 
surrogate for worsening kidney function, with a magnitude of effect that was comparable to the one seen in the TEMPO 3:4 study (35%; p < 0.0001).  Taken together, the results of these two studies demonstrate that the efficacy of vasopressin antagonism is maintained across multiple time periods and stages of disease.  
The evidence supporting the potential utility of lixivaptan for the treatme nt of ADPKD is 
provided by experiments in an animal model of PKD and by the clinical effect of lixivaptan on urine osmolality, a pharmacodynamic biomarker of effective vasopressin antagonism that is correlated with efficacy in ADPKD , as discussed below.  
Lixivaptan ameliorates disease manifestations in the PCK rat model of PKD 
The PCK rat, an orthologous model of human polycystic kidney disease (PKD) caused by a 
splicing mutation in the pkhd1 gene, is one of the best-studied models in the field of PKD research because it is characteri zed by a phenotype that is highly reminiscent of human 
disease.
10  Compared to control animal s, PCK rats treated with lixivaptan showed a marked 
protective effect on the development of kidney disease manifestations, including reduced cystic burden , reduced renal volume increase, and delayed renal function decline.  These  
beneficial effects were accompanied by a reduction in renal cAMP levels, as expected .  
Additional background information on the effect of lixivaptan in the PCK rat can be found in the Investigator Brochure (IB).  
Lixivaptan causes sustained suppression of urine osmolality to levels that are associated with therapeutic efficacy in ADPKD  
Palladio Biosciences  PA-102 Page 18 of 66 
 
21-Mar-2019  Confidenti al Information  Version 5  The expectation about the efficacy of lixivaptan in ADKPD is supported by the observed 
clinical effects of lixivaptan on the pharmacodynamic biomarker of urinary osmolality .  
Clinical studies conducted with lixivaptan in healthy subjects and various patient populations 
(patients with hypervol emic and euvolemic hyponatremia and patients with ESRD) 
demonstrated that treatment with lixivaptan readily suppressed urinary osmolality to levels below the target threshold of 300 mOsm/kg, irrespective of the specific  patient population 
tested .  Importantly, the magnitude of the effect observed with lixivaptan wa s comparable to 
the effect observed with tolvaptan in the same patient populations.  In addition, like 
tolvaptan, treatment with lixivaptan was associated with  a rapid -onset and fully reversible 
increase in serum creatinine. Taken together, these results suggest that treatment with 
lixivaptan can inhibit vasopressin receptor signaling to the extent necessary to observe 
clinical efficacy of a vasopressin antagoni st for the treatment of ADPKD.
14   
Additional background information on the effect of lixivaptan on urine osmolality can be 
found in the Investigator Brochure (IB). 
1.5 Summary of Nonclinical Studies  
Experiments in rats and dogs, with or without pretreatment with vasopressin, and with or 
without free access to water, confirm ed that lixivaptan is a potent vasopressin V 2 receptor 
antagonist. Compared with conventional diuretics, lixivaptan increased urinary volume output about 3 to 4 times more than furosemide or hydrochlorothiazide at comparable doses and decreased urinary osmolality.  Four identified human metabolites of lixivaptan (WAY -
137930, WAY -138451, WAY -138758, and WAY -141624) were found to be weakly active or 
inactive as vasopressin V
2 receptor antagonists as assessed by in vitro receptor binding and in 
vivo aquaretic studies in rats.   
Studies using rodent genetic models have demonstrated that inhibiting vasopressin signaling 
is protective against the development of PKD.  Rats genetically crossed to produce offspring with no circulating serum vasopressin, and that harbor a renal cyst inducing PKD mutation, do not develop cysts.
8  In addition, the V 2 vasopressin receptor antagonists mozavaptan and 
tolvaptan can normalize renal cAMP and correct disease manifestations in rodent models of ADPKD.
9,10  Similarly, t he vasopressin V 2 receptor antagonist lixivaptan reduces renal cAMP 
levels in a rodent model of PKD and is also protective against the development of kidney disease manifestations, including reduced cystic burden, reduced renal volume increase, and delayed renal function decline.  Additional information regarding the nonclinical evaluation of lixivaptan  can be found in the Investigator Brochure.  
1.6 Summary of Clinical Studies  
Lixivaptan is a novel, highly selective, non-peptide, vasopressin V 2 receptor antagonist .  It 
was previously developed for treating disease states associated with water retention , e.g. 
euvolemic and hypervolemic hyponatremia .  Pharmacokinetic ( PK), safety , tolerability and 
efficacy data for lixivaptan are available from 36 clinical studies, including 22 P hase 1 
studies in healthy and/or CKD subjects, 10 Phase 2a studies and 4 Phase 3 studies in subjects with hyponatremia .  More than 1600 subjects received at least one dose of lixivaptan as part 
of the hyponatremia development program, including 867 who participated in Phase 2 and 3 
Palladio Biosciences  PA-102 Page 19 of 66 
 
21-Mar-2019  Confidenti al Information  Version 5  studies.  Lixivaptan was generally safe and well -tolerated in this patient population.  T he 
most common adverse events (AE)  were headaches, dizziness, thirst, orthostatic hypotension, 
and t achycardia events .   
Additional information regarding the clinical evaluation of lixivaptan  can be found in the IB. 
Even though lixivaptan was never tested in ADPKD patients , proof of concept for the 
potential utility of lixivaptan for the treatment of ADPKD is provided by the vasopressin V 2 
receptor antagonist tolvaptan.  Results from the TEMPO 3:4 P hase 3 trial led to approval in 
Europe for the use of tolvaptan to slow the progression of cyst development and renal 
insufficiency of ADPKD in adults with CKD stage 1 to 3.  The TEMPO 3:4 trial showed that 
tolvaptan slow ed the progression of kidney enlargement and delayed the worsening of kidney 
function.12  The study also established suppression of urine osmolality to <  300 mOsm/kg a s 
a predictive pharmacodynamic marker of clinical efficacy for a vasopressin V2 antagonist for 
the treatment of ADPKD.  More recently , the REPRISE P hase 3 study with tolvaptan 
demonstrated that the efficacy of vasopressin V 2 receptor antagonism is maintained in 
patients with later stage ADPKD.15   
1.7 Study Rationale  
This study is being conducted to directly characterize the pharmacokinetic (PK), safety, and 
pharmacodynamic (PD) profiles of lixivaptan following administration of twice per day (BID) oral doses of 50 and  200 mg for 7 days in subjects with both autosomal dominant 
polycystic kidney disease (ADPKD) and chronic kidney disease (CKD) stage 1 (CKD1), stage 2 (CKD2) or stage 3 (CKD3).  These proposed PK, safety, and PD assessments will be used to guide appropriate lixivaptan dosing recommendations for subjects wi th ADPKD and 
mild or moderate CKD.  
1.8 Dose Rationale  
The human equivalent exposure range of lixivaptan proposed by this study has been shown to be safe and tolerated in nonclinical animal studies and previous clinical studies conducted in healthy subject s and  in subject s with hyponatremia of various etiologies.   
As noted above, the selected doses are based on expected effect on urine osmolality. These 
doses w ere considered appropriate for the PK/PD evaluation of lixivaptan in subject s with 
ADPKD and mild or m oderate CKD.  
Palladio Biosciences  PA-102 Page 20 of 66 
 
21-Mar-2019  Confidenti al Information  Version 5  2 STUDY OBJECTIVES  AND ENDPOINTS  
2.1 Study  Objective s 
2.1.1 Primary Objective s 
The primary objectives of this study are: 
• To characterize the safety and tolerability of lixivaptan following multiple doses in 
ADPKD subjects with relatively preserved kidney function (CKD1 and CKD2) and moderately impaired renal function (CKD3) ; and  
• To characterize the PK profile of lixivaptan and its major metabolites ( WAY -141624, 
WAY -138451, and WAY -138758) following multiple doses of lixivaptan in ADPKD 
subject s with relatively preserved kidney function (CKD1 and CKD2) and moderately 
impaired renal function (CKD3). 
2.1.2 Secondary Objectives 
The secondary objectives of this study are:  
• To characterize the effect of lixivaptan on  urine osmolality over a 24-hour peri od 
following multiple  doses of lixivaptan in ADPKD subject s; and  
• To characterize the time course of the pharmacodynamic effect of lixivaptan on urine 
output , total kidney volume, liver volume, plasma  copeptin and s erum creatinine in 
ADPKD subject s.  
2.2 Study Endpoint s 
2.2.1 Primary Endpoint s 
• The following PK parameters will be calculated using noncompartmental methods, whenever possible, based on the plasma concentrations of lixivaptan and its major  
metabolites ( WAY -141624, WAY -138451, and WAY -138758) , for lix ivaptan and each 
metabolite:  maximum observed plasma drug concentration (C
max), time to reach 
maximum plasma concentration (t max), area under the plasma concentration -time 
curve ( AUC ) from time 0 until the last quantifiable concentration (AUC 0-t), AUC 
extrapolated to infinity (AUC 0-inf), terminal elimination phase half -life (t 1/2), apparent 
terminal elimination rate constant (λ z), total body clearance (CL/F ; lixivaptan  only ), 
and volume of distribution (Vz/F ; lixivaptan  only). 
• The safety and tolerability o f lixivaptan will be assessed  through evaluation of 
physical examination findings, vital signs, 12- lead electrocardiograms ( ECG ), clinical 
laboratory findings ( clinical chemistry , hematology  and urinalysis), assessments of 
adverse events (AE) and a q uestionnaire assessing aquaretic tolerability (symptom 
burden of nocturia, urgency, frequency ). 
Palladio Biosciences  PA-102 Page 21 of 66 
 
21-Mar-2019  Confidenti al Information  Version 5  2.2.2 Secondary Endpoint s 
The effect of lixivaptan on  urine osmolality by lixivaptan  will be determined through 
evaluation of: 
• Spot urine osmolality  and 24h urine output. 
The pharmaco dynamic effect s of lixivaptan  will be determined through evaluation of: 
• Serum creatinine, blood urea nitrogen ( BUN), and estimated glomerular filtration rate 
(eGFR ); 
• Total kidney volume (TKV) and liver volume (LV) measured by abdominal mag netic 
resonance imaging (MRI); and  
• Plasma copeptin, as a marker for circulating vasopressin . 
Palladio Biosciences  PA-102 Page 22 of 66 
 
21-Mar-2019  Confidenti al Information  Version 5  3 INVESTIGATIONAL PLAN 
3.1 Study Design  
This is  a Phase 2, open-label, parallel -group, multiple dose study designed to evaluate the 
PK, PD, safety, and tolerability of  multiple BID doses of 50 and 200 mg lixivaptan  in 
ADPKD subjects with chronic kidney disease in stages CKD1, CKD2 or CKD3 .  The study 
will be conducted at multiple  Clinical Research Units ( CRUs ) in the United States ( US). 
For all subjects , this study includes a Screening period of 42 days (Day -44 through Day -3), 
i.e. up to 44 days  prior to dosing on Day 1.  Subjects will be confined to the CRU on two 
separate occasions, with a total period of confinement of up to 7 days  and 5 nights.  The first  
confinement period will last up to 4 days  (up to 3 nights).  Subjects will be admitted  to the 
CRU in the afternoon of Day -2 or, depending on travel arra ngements, in the morning of Day 
-1, and will be domiciled until discharge from the CRU in the morning of Day 2.  The second  
confinement period will last 3 days  (2 nights).  Subjects will return to the CRU to be 
admitted  in the afternoon of Day 6 and will be discharged from the CRU in the morning of 
Day 8.   Alternatively, s ubjects  may be offered the option to remain admitted to the CRU for 
the entire duration of the dosing period, i.e. from  the initial admission on  Day -2 (or Day -1 
where applicable) until discharge on Day 8.   
Except for the AM and PM doses on Days 1, 6, and 7, and the AM doses on Days 2, 4 and 6, 
all other doses will be self -administered  by the subject .  Subjects will be required to record 
self-administered doses in a Study Dosing Diary (Section 5.7.1).  
Enrolled subjects will be assigned according to CKD classification to take one of 2 dose 
regimens ( Table 5-1) for 7 days .  Each dose regimen includes morning (AM) and evening 
(PM) oral administration of lixivaptan .  Doses will be administered with ap proximately 10 
hours separation between the AM and PM doses as follows.  When subjects are confined to the CRU, the PM dose will be administered 10 ± 0.25 hours after the AM dose .  When 
lixivaptan is self -administered, t he PM dose will be administered  10 ± 1.0 hours after the AM 
dose.  Subject s will maintain adequate hydration throughout the study by adhering to a 
predetermined daily fluid intake regimen  (Section  5.9).  
To be enrolled, subjects must meet the following diagnostic criteria for ADPKD (modified Pei-Ravine criteria):  
• For subject s with fa mily histo ry of ADP KD, a minimum of  3 cys ts per kidney by 
sonograph y or 5 cy sts by computerized tomography ( CT) or magnetic resonance 
imaging ( MRI); or 
• For subject s without fa mily histo ry of ADP KD, a minimum of  10 cy sts per kidney by 
any radiolog ic method and exclusion of other cy stic kidney diseases. 
Subjects may be enrolled if they meet the modified Pei- Ravin
 e criteria, have a confirmed 
CKD Classification  of CKD1, CKD2 or CKD3 ( Table 3-1 and  see Appendix 1), and meet the 
other inclusion/exclusion (I/E) criteria (Section 4.1).   
Palladio Biosciences  PA-102 Page 23 of 66 
 
21-Mar-2019  Confidenti al Information  Version 5  Table 3-1 Chronic Kidney Disease  Classification  Summary  
CKD Classification  Cohort s N eGFR * 
    
CKD1  or CKD2 ** 1 and 3  16 (8 per cohort)  eGFR ≥ 60 mL/min/1.73 m2 
    
CKD3  2 and 4  16 (8 per cohort)  eGFR ≥ 30 to < 60 mL/min/1.73 m2 
    
Abbreviations: CKD  = chronic kidney disease, eGFR  = estimated glomerular filtration rate , 
N = number  of subject s. 
*eGFR  is calculated  by the 2009 Chronic Kidney Disease Epidemiology Collaboration (CKD -EPI) equation 
(Appendix 1).   
**At least 2 subjects with CKD1 or CKD2 will be included in 8 subjects assigned to  Cohorts 1 and 3.  
Subjects may be allowed to re -screen or have repeat testing after agreement between the 
investigator and medical monitor.   Lab tests that need to be repeated during Screening may 
be obtained through the services of an at-home nursing service provided by the Sponsor. 
Subjects who withdraw early from the study may be replaced at the discretion of the 
Investigator and of the Sponsor to ensure that approximately 32 subject s (8 subject s in 
CKD1/2 and 8 subject s in CKD3  per dose level, see Table 5-1)  complete the study.  
Study assessments including PK blood sampling, urine collection, PD blood sampling, 
physical examination findings , vital signs, ECGs , clinical laboratory tests, and  monitoring of 
AEs will be performed at the timepoints presented in  Table 12-1.  Adverse events and serious 
AEs (SAE)  that are related to stud y participation (e.g., protocol- mandated intervention) will 
be recorded from the time the subject  signs the Informed Consent For m (ICF) until the start 
of lixivaptan dosing.  All other AEs and SAEs will be recorded from the start of lixivaptan dosing until exit from the study .  Assessment windows are presented in  Table 12-2.  
3.1.1 Rationale of Study Design  
The I/E criteria in S ection  4.1 were chosen to recruit an adequate number of subjects 
representative of the ADP KD population to achieve the study’ s primary objectives as 
presented in S ection  2.1.1.   
Based on existing clinical evidence with lixivaptan and the related vasopressin antagonist tolvaptan, the PK and PD properties of lixivaptan are not expected to differ in ADPKD subjects with CKD1 and CKD2 stages, therefore these subjects with relatively preserved kidney function will be combined into one study group.  This approach decreases the total number of subjects that need to be recruited without compromising the study obj ectives.  
Conversely, subjects with moderately impaired renal function (CKD3 stage) may show distinct PK and PD responses to lixivaptan and will be enrolled into a separate group. 
The PK profile of lixivaptan and its metabolites will be monitored for 3-5 h alf-lives after the 
last dose to define terminal PK parameters.  Therefore, PK blood draws are included up to 96 
hours, i.e. approximately 4 half -lives of the longest- lived metabolite of lixivaptan, after the 
last dose of lixivaptan (Day 7 PM).   
Palladio Biosciences  PA-102 Page 24 of 66 
 
21-Mar-2019  Confidenti al Information  Version 5  Treatment  with lixivaptan is associated with transient and reversible increases in serum 
creatinine and circulating  vasopressin.  In addition, based on clinical evidence with the 
related vasopressin antagonist tolvaptan,12 lixivaptan may be associated with transient and 
reversible decreases in Total Kidney V olume (TKV).  In order to characterize the time course 
and magnitude of these pharm acodynamic effects of lixivaptan in ADPKD subjects, the study 
design includes measurements of serum creatinine, plasma copeptin as a marker for circulating  vasopressin, and TKV at three time points: at baseline, after completion of the 
scheduled treatment period and 4 weeks after the last dose of lixivaptan.   
The sample size of 32 subject s in total, with 16 subjects per Cohort, is typical for this type of 
study and is considered adequate to meet the study objectives. 
Palladio Biosciences  PA-102 Page 25 of 66 
 
21-Mar-2019  Confidenti al Information  Version 5  4 SUBJECT  SELECTION AND WITHDRAWAL CRITERIA  
4.1 Selection of Study Population  
Approximately 32 subjects will be enrolled at approximately 15 sites  (or more as necessary 
to recruit subject s) in the US .  Subject s will be assigned to study treatment only if they meet 
all of the inclusion criteria and none of the exclusion criteria. 
Deviations from the inclusion and exclusion criteria are not allowed because they can 
potentially jeopardize the scientific integrity of  the study, regulatory acceptability, or subject  
safety.  Therefore, adherence to the criteria as specified in the protocol is essential . 
4.1.1 Inclusion Criteria  
In order to qualify for enrollment in this study, each subject must meet the following 
inclusion cr iteria : 
1. Capable of understanding the written informed consent, provides signed and witnessed written informed consent, and agrees to comply with protocol requirements and study- related procedures.  
2. Male or female, between 18 and 65 years of age (inclusive) at the time of Screening.  
3. Body mass index (BMI) between 18 and 35 kg/m
2 (inclusive) at the time of 
Screening.  
4. Estimated glomerular filtration rate ( eGFR ) ≥ 60 mL/min/1.73 m2 (Cohort 1 and 3), 
or eGFR ≥ 30 to < 60 mL/min/1.73 m2 (Cohort 2 and 4) , with eGFR calculated by the 
CKD- EPI equation (Section 12.1). 
5. Subject  has been diagnosed with ADPKD by modified Ravine criteria:  
• For subject s with family history o f ADPKD, a minimum of  3 cysts per kidney by 
sonography or 5 cysts by CT or MRI; or 
• For subject s without family history of ADPKD, a minimum of 10 cysts per 
kidney by any radiologic method and exclusion of other cystic kidney diseases.   
To verify the cyst count, medical records may be used in association with the Screening visit.  Alternatively, in the absence of sonography or radiography evidence from medical records , subjects may be included at the discretion of the Investigator 
until a modified Ravine diagnosis can be confirmed through the baseline MRI assessment (see section 6.1.6).   
6. Considered by the Investigator to be in good health relative to underlying CKD status and clinically stable with respect to underlying CKD, based on medical evaluation that includes medic al and surgical history, as well as a complete physical examination 
including vital signs, ECG, and laboratory test results.  A single repeat assessment is permitted for any laboratory, ECG, or vital sign parameter required for enrollment. 
7. Female subjects must: 
• be non-pregnant and non- lactating; 
Palladio Biosciences  PA-102 Page 26 of 66 
 
21-Mar-2019  Confidenti al Information  Version 5  • be either postmenopausal (defined as amenorrhea for ≥  12 months and, if 
confirmation is necessary based on Investigator discretion, a confirmed follicle 
stimulating hormone [FSH] ≥  40 mIU/mL), surgically sterile (de fined as having 
undergone hysterectomy and/or bilateral oophorectomy), practice total abstinence from sexual intercourse as the preferred lifestyle (periodic abstinence is not acceptable), or agree to use an appropriate method of birth control consistently throughout the study and continue to use this method for 30 days after study drug administration.  
Double barrier methods of non-hormonal contraception are permitted in this study.  Acceptable forms of contraception include the following:  
 intrauterine devi ce, including Mirena
® 
 female condom with spermicide (cream, spray, gel, suppository, contraceptive sponge, or polymer film) 
 diaphragm with spermicide (with or without a condom) 
 cervical cap with spermicide (with or without a condom) 
 male sexual partner who  agrees to use a male condom in addition to female 
subject ’s use of spermicide (cream, spray, gel, suppository, contraceptive 
sponge, or polymer film) 
 male sexual partner who has been vasectomized for at least 3 months prior to Screening and who has obtained a follow-up negative sperm count 
 bilateral tubal ligation  
 Essure
® procedure  
Estrogen -based hormonal contraception is not permitted in this pharmacokinetic 
study due to the potential for interaction with lixivaptan.   
8. Male subjects who are sexually activ e with a partner of child- bearing potential must 
either be sterile (vasectomy with history of a negative sperm count following the procedure); practice total abstinence from sexual intercourse as the preferred lifestyle (periodic abstinence is not acceptable); use a male condom with any sexual activity; or agree to use a birth control method considered to be appropriate by the Investigator (such as  hormonal contraception or one of the methods identified above for female 
subjects of childbearing potential) f rom the time of Screening until 90 days after 
study drug administration.  Male subjects must agree not to donate sperm for a period of 90 days after study drug administration. 
9. Patients who are smokers will be allowed to smoke ≤  10 cigarettes per day during the 
study.  
10. Subjects must be willing to be confined to the CRU for the entire duration required by the protocol, able to comply with all study- related requirements and able to adhere to 
study restrictions and visit schedules. 
Palladio Biosciences  PA-102 Page 27 of 66 
 
21-Mar-2019  Confidenti al Information  Version 5  4.1.2 Exclusion Criteria 
Subject s meeting any of the following exclusion criteria are not eligible for study enrollment.  
1. Subjects with  known sensitivity or idiosyncratic reaction to any compound present in 
lixivaptan, its related compounds su ch as benzazepine s (e.g., tolvaptan, conivaptan, 
bena zepril, fenoldopam, or mirtazapine), or any compound listed as being present in 
the study formulation.  
2. Women who are pregnant or breast feeding. 
3. Subjects who have taken any investigational drug or used an investigational device 
within 30 days or 5 half-lives, whichever is longer, prior to Day 1. 
4. Subjects who have taken tolvaptan, conivaptan, somatostatin analogs (e.g. lanreotide, pasireotide, octreotide, etc.), mTOR kinase inhibitors (e.g. everolimus, sirolimus, etc.), or oral or intravenous antibiotics  within 30 days or 5 half-lives, whichever is longer, 
prior to Day 1. 
5. Subject s will be allowed to take their chronic medications unless excluded by the 
protocol (Section 5.8.2) and provided that their chronic medication therapy meets the 
conditions outlined in Section 5.8.1, including remain ing constant throughout the 
duration of the study.  
6. Subjects who have taken, or are expected to be taking,  strong or moderate CYP3A4 or 
CYP2C8 inhibitors (e.g. aprepitant , boceprevir, clarithromycin, chloramphenicol (not 
eye drops), cimetidine, ciprofloxacin, clopidogrel, clotrimazole (if used orally), cobicistat and cobicistat -containing products, crizotinib, cyclosporine, danazol, 
deferasirox , diltiazem, dronedarone, erythromycin, fluconazole, fluvoxamine, 
gemfibrozil, HIV protease inhibitors, imatinib, isoniazid, itraconazole, josamycin, ketoconazole, nefazodone, posaconazole, quinupristin/dalfopristin, ritonavir and ritonavir-containing products, telaprevir, teriflunomide, tofisopam, troleandomycin, verapamil, voriconazole ) within 14 days or 5 half-lives, whichever is longer, of 
dosing;  or weak CYP3A4 or CYP2C8 inhibitors (e.g.c hlorzoxazone, cilostazol, 
fosaprepitant, istradefylline, ivacaftor, lomitapide, ranitidine, r anolazine, tacrolimus, 
ticagrelor , trimethoprim) within 7 days or 5 half -lives, whichever is longer, from 
dosing.  For weak CYP3A4 or CYP2C8 inhibitors, medications may be allowed in consultation with the Medical Monitor (MM).  
7. Subjects who have taken, or are expected to be taking,  strong or moderate CYP3A4 or 
CYP2C8 inducers (e.g. barbiturates, bosentan, carbamazepine, efavirenz, enzalutamide, etravirine , modafinil, mitotane, nevirapine, oxcarbazepine, phenytoin, 
pioglitazone, rifabutin, rifampin, St. John’ s wort) within 14 days or 5 half-lives, 
whichever is longer, of dosing ; or weak CYP3A4 or CYP2C8 inducers (e.g. 
armodafinil, rufinamide) within 7 days or 5 half -lives, whichever is longer, from 
dosing.  For weak CYP3A4 or CYP2C8 inducers , medications may be allowed in 
consultation with the Medical Monitor (MM).  
8. Subject  who have a transplanted kidney, or absence of a kidney. 
Palladio Biosciences  PA-102 Page 28 of 66 
 
21-Mar-2019  Confidenti al Information  Version 5  9. Subjects with a history of clinically significant drug or alcohol abuse within the past 5 
years . 
10. Subjects with a history of testing p ositive for hepatitis B surface antigen (HBsAg), 
hepatitis C (HCV), or human immunodeficiency virus (HIV). 
11. Subjects who have consumed grapefruit or Se ville oranges (or their juices , or foods 
containing their extract ) from 7 days prior to the first dose of study medication and 
until after the final dose . 
12. Subjects with clinically significant incontinence, overactive bladder, or urinary retention (e.g., be nign prostatic hyperplasia) . 
13. Subjects with clinically significant nocturia/urgency at Screening  outside of the 2 to 4 
times awakening per night expected for ADPKD patients. 
14. Subjects with clinically significant liver disease, or clinically significant liver  function 
abnormalities or serology other than that expected for ADPKD with cystic liver disease at baseline.  
15. Subjects with a spartate aminotransferase (AST), alanine aminotransferase (ALT), 
gamma -glutamyltransferase (GGT) , alkaline phosphatase (ALP) or total bilirubin ≥  
1.5 × upper limit of normal (ULN) at Screening.   Subjects with elevated bilirubin due 
to Gilbert’s Syndrome may be allowed at the discretion of the Investigator. 
16. Subjects w ith any histo ry of si gnificant bl eeding or hem orrhagic tendenci es. 
17. Subjects w ith cont raindications to or int erference w ith M RI assessments 
(ferromagne tic meta l prostheses, aneury sm clips, sever e claustrophobia, or large 
abdominal/back tattoos ) 
will be excused from this procedure, but may participate in the 
study  providing that all other eligibility criteria are met .  Investigator should seek MRI 
safety guidance from  the local MRI facility.  
18. Subjects who have experienced an illness that is considered by the Investigator to be clinicall y significant within 2 weeks of study drug administration on Day 1. 
19. Subjects with a history of difficulty in donating blood, or who have donated or lost a significant volume (>  450 mL) of blood within 56 days, or plasma within 7 days, prior 
to Day -1. 
20. Subjects who are unable to swallow medication.  
21. Subjects who participated in strenuous exercise within 48 hours prior to Check-in (Day - 1). 
22. Subjects with New York Heart Association Functional Class 3 or 4 heart failure.
  
23. Exclusion criteria for Screening ECG (a single repeat i s allowed for eligibility 
determination):  
• Sinus pauses > 3 seconds. 
• Any significant arrhythmia or conduction abnormality, which, in the opinion of the Investigators and Medical Monitor, could interfer e with the safety for the 
individual subject. 
Palladio Biosciences  PA-102 Page 29 of 66 
 
21-Mar-2019  Confidenti al Information  Version 5  • Non-sustained or sustained ventricular tachycardia, or ≥  3 consecutive 
ventricular ectopic beats.  
24. Subjects with a ny clinically significant concomitant disease or condition other than 
ADPKD (including treatment f or such conditions) that, in the opinion of the 
Investigator, could either interfere with the study drug or pose an unacceptable risk 
to the subject. 
25. Subjects with any other clinically significant abnormalities in laboratory test results at Screening that would, in the opinion of the Investigator, increase the subject's risk of participation, jeopardize complete participation in the study, or compromise interpretation of study data. 
26. Subjects who have experienced elevated AST or ALT (defined as ≥  2.0 × ULN) while 
taking tolvaptan. 
27. Any other reason, e.g. serious mental disorders, that  would render the subject 
unsuitable for study enrollment at the discretion of the Investigator. 
4.2 Withdra wal of Subject s from the Study  
The duration of the study is defined for each subject as the date signed written informed consent is provided through the End of Study assessment , which will be on Day 35 or the 
date of Early Termination  (ET) for subject s who are withdrawn prior to the End of Study 
assessment . 
4.2.1 Reasons for Withdrawal /Discontinuation  
Subject s may withdraw from the study at any time and for any reason without prejudice to 
their future medical care by the Investigator or at the study site.  Every effort should be made 
to keep subject s in the study and, in the case of voluntary withdrawal, to inquire as to the 
reason(s) for withdrawal .  The reasons for subjects not completing the study will be recorded. 
If a subject withdraws for any reason after having received study drug, the subject will be asked to complete ET procedures, which will be the same as those scheduled to be performed prior to discharge from the CRU on Day 8.  If a subject voluntarily withdraws before receiving the study dr ug, no additional safety assessments or testing will be required. 
A subject  may be withdrawn from the study for any of the following reasons: 
1. Does not meet the protocol inclusion or exclusion criteria. 
2. Noncompliance with the protocol. 
Palladio Biosciences  PA-102 Page 30 of 66 
 
21-Mar-2019  Confidenti al Information  Version 5  3. A serious or intolera ble AE that , in the Investigator’s opinion, requires withdrawal 
from the study, including but not limited to  laboratory safety assessments that reveal 
clinically significant (CS) hematological or biochemical changes from the baseline 
values , other than changes that are expected for vasopressin antagonists, and 
symptoms or an intercurrent illness that justifies withdrawal.  M ild elevation s in serum 
creatinine or serum sodium are known pharmacodynamic effects of vasopressin antagonists like lixivaptan  and are transient and reversible.  Therefore, patients should 
not be withdrawn due to mildly elevated serum creatinine or serum sodium.  Cases 
where eGFR has declined by 25% or more from baseline should be discussed with the Medical Monitor. 
4. Lost to follow-up. 
5. Other (e .g., pregnancy, development of contraindications of use of study drug). 
6. The subject  withdraws consent, or the Investigator or Sponsor decide to discontinue 
the subject ’s participation in the study.  
7. The Investigator will also withdraw a subject if  the Sponsor t erminates the study . 
Upon occurrence of a serious or intolerable AE, the Investigator will confer with the Sponsor.  If a subject  is discontinued because of an AE, the event will be followed until it is resolved or 
stable as determined by the Investigator .  Any subject  may withdraw his or her consent at any 
time.  
Subject safety will be closely monitored throughout the study and the study will be conducted following GCP.  The entire study may be stopped at any time at the discretion of the Inves tigator in consultation with the Sponsor. 
4.2.2 Handling of Withdrawals  
Subjects are free to withdraw from the study or study treatment at any time.  Subject  
participation in the study may be stopped at any time at the discretion of the I nvestigator or at 
the request of the Sponsor. 
Subject s who discontinue study treatment or active participation in the study will no longer 
receive study drug.   When a subject  withdraws from the study, the reason(s) for withdrawal 
shall be recorded by the Investigator on the relevant page of the electronic case report form 
(eCRF ).  Whenever possible, all subject s who discontinue study treatment or withdraw from 
the study prematurely will undergo all end-of- study assessments at  the time of ET .  Subject s 
who fail to return for final assessments will be contacted by the site in an attempt to have 
them comply with the protocol.  Methods for follow up will consist of 2 documented phone calls followed by 1 registered letter.  
It is vital to obtain follow -up data on any subject withdrawn because of an AE or SAE.  In 
every case, efforts must be made to undertake protocol-specified, safety, follow-up procedures. 
Palladio Biosciences  PA-102 Page 31 of 66 
 
21-Mar-2019  Confidenti al Information  Version 5  4.2.3 Replacements  
If the Investigator withdraws a subject  for a reason rel ated to the study drug (in the opinion 
of the Investigator), then the subject  is considered discontinued from the study.  Discontinued 
subject s will be replaced if deemed necessary by the Sponsor. 
If a subject  does not complete the study for a reason that is unrelated to the study drug, the 
subject  may be replaced if the Sponsor instructs the site to do so.  The decision regarding the 
replacement of subject s will be documented. 
Palladio Biosciences  PA-102 Page 32 of 66 
 
21-Mar-2019  Confidenti al Information  Version 5  5 STUDY TREATMENTS  
5.1 Method of Assigning Subject s to Treatment Groups  
Each subject  will be assigned a screening number.  Once enrolled into the study, subject s will 
be assigned a unique subject  number starting with a 2 digit site number, followed by a unique 
2 digit subject  number.     
Subject s who replace discontinuing subject s after the  first study drug administration has 
taken place will be assigned their own unique subject number and same cohort assignment as 
the subject being replaced.  
5.2 Blinding and Randomization  
This is an open-label study and no blinding procedures will be used.  Following enrollment, 
subjects  will be centrally assigned to one of 4 cohorts depending on CKD status ( Table 5 -1) 
and based on a predetermined algorithm.  The 200 mg BID dose cohorts will be enrolled 
first.  At least 2 males or females will be included in the 8 subjects (i.e., can be up to a 
25%/75% spl it of male/female or 75%/25% split of male/female)  assigned to each cohort. 
Similarly, at least 2 subjects with CKD1 or CKD2  will be included in  8 subjects each  
assigned to  Cohorts 1 and 3. 
5.3 Treatments Administered  
Subject s assigned  to one of the 2 dose levels of lixivaptan ( Table 5-1) will receive oral 
lixivaptan BID (AM and PM) from Day 1 through Day 7.  The PM dose will be administered 
approximately 10 hours after the AM dose. 
Table 5-1 Study Cohorts and Lixivaptan Dose Levels 
Cohort CKD stage  Dose * N  
1 CKD1 or CKD2  200 mg BID 8 subjects Candidate 
maximum tolerated dose 
2 CKD3  200 mg BID 8 subjects 
3 CKD1 or CKD2  50 mg BID 8 subjects Candidate lowest effective dose  
4 CKD3  50 mg BID 8 subjects 
*PM dose to  be administered approximately 10 hours after the AM dose  
Prior to the morning doses on Days 1 and 7, subjects will fast overnight for ≥ 8 hours prior to 
study medication administration .  Water will be allowed ad libitum  during the overnight 
fasting.  Liquids (other than water) are considered part of the ≥  8 hour overnight fast . 
In the morning of Days 1 and 7, s ubjects will receive lixivaptan with room temperature water  
(approximately 240 mL [8 ounces]) and will remain fasted for 2 hours after  dosing.  Water 
Palladio Biosciences  PA-102 Page 33 of 66 
 
21-Mar-2019  Confidenti al Information  Version 5  will be allowed ad libitum  during the 2 hours fasting, however subjects will be required to 
abstain from consuming other liquids until 2 hours after dosing.   
The evening doses on Days 1 and 7 will be administered in the CRU under fasting 
conditions, i.e. 2 hours before and 2 hours after meals.  Liquids (other than water) are 
considered part of the 2 hour fast . 
Study drug will be administered orally to subjects.  Administration of each dose of study drug 
while the subject is confined at the CRU will be supervised, verified, and documented according to the CRU ’s standard operating procedures.  A mouth and hand check will be 
performed immediately after study drug administration.  
The actual date and time of each dose administration will be entered in the eCRF . 
When not confined to the CRU, s ubjects will self -administer lixivaptan with water  
(approximately 240 mL) and without fasting.  Subjects will continue to adhere to the recommended fluid intake regimen outlined in Section 5.9. 
5.4 Identity of Investigational Product  
The Sponsor will provide adequate supplies of lixivaptan  for use during the study as shown 
in Table 5-2. 
Table 5-2 Investigational Product 
 Lixivaptan  
Strength  50 mg  
Formulation Capsules  
Batch Number  B17121A1 
Supplier/  
manufacturer  Palladio Biosciences  
12 Penns Trail , Unit A  
Newtown, PA 18940 PMRS, Inc.  
202 Precision Road  Horsham, PA 19044 
 
5.5 Management of Clinical Supplies  
5.5.1 Study Drug Packaging and Storage  
Lixivaptan 50 mg capsules are packaged in HDPE bottles with desiccant .  Each bottle 
contains thirty 50 mg capsules and is labeled with protocol number and necessary regulatory statements.  
All investigational drug supplies should be stored in a secure, locked area under the 
responsibility of the Investigator or other authorized individual.  Lixivaptan 50 mg  capsules  
must be stored under refrigerated conditions between 2-8°C (36-46°F) in tightly closed containers and protected from extreme conditions of temperature, light and humidity. While subjects are confined to the CRU, dos es of l ixivaptan  will be prepared and dispensed by the 
Investigator or a qualified designee.  When subjects are not confined to the CRU, they should 
Palladio Biosciences  PA-102 Page 34 of 66 
 
21-Mar-2019  Confidenti al Information  Version 5  be instructed to store study drug in its original packaging under refrigerated conditions until 
ready to take.  
Unused study medication dispensed to and returned by a study subject should be stored under refrigerated conditions until returned to the Sponsor or designee or destroyed according to 
applicable regulations. 
5.5.2 Test Article Accountability  
The Investigator will maintain accurate records of study drug receipt  and disposition.  In 
addition, accurate records will be kept regarding when and how much test article is dispensed and used by each subject  in the study.  Reasons for departure from the expected dispensing 
regimen must also be recorded.  At the completion of the study, to satisfy regulatory requirements regarding drug accountability, all unused study drugs will be reconciled and retained , returned to the Sponsor or designee, or destroyed acco rding to applicable 
regulations. 
5.6 Overdose Management  
An overdose is any dose of study treatment given to a subject  or taken by a subject  that 
exceeds the dose described in the protocol.  Any overdose, with or without associated AEs, 
must be promptly reported to the Investigator and also reported to the Sponsor.  Overdoses without signs or symptoms do not need to be recorded as AEs; in case of any AEs associated 
with the overdose, these should be reported on relevant AE/SAE sections in the eCRF. 
5.6.1 Treatment of Overdose  
In the event of suspected overdose, the appropriate supportive clinical care should be instituted  at the discretion of the Investigator or  as dictated by the subject ’s clinical status.  
5.7 Treatment Compliance  
When subjects are confined at the CRU, each dose of study drug will be administered by the Investigator or qualified designee.  A hand and mouth check will be performed immedia tely 
after each study drug administration to verify that the study drug was swallowed.  The determination of plasma concentrations of lixivaptan  during the analytical phase will provide 
further confirmation of treatment compliance.  
Subjects will maintain a  diary of outpatient administration of lixivaptan  as described below.   
5.7.1 Study Dosing Diary 
Subjects will maintain a Study Dosing Diary for the duration of the outpatient treatment period (Day 2 to Day 6) and during the week immediately following the last dose of lixivaptan (PM dose on Day 7).  Subjects will be asked to record in the Study Dosing Diary each self -administered dose of lixivaptan , including date and time of dose and number of 
capsules taken, any subject -reported AEs and any other medications ta ken, including over-
the-counter medications.  
Palladio Biosciences  PA-102 Page 35 of 66 
 
21-Mar-2019  Confidenti al Information  Version 5  Subjects will be asked to bring the Study Dosing Diary together with their unused study 
product at each scheduled visit to the CRU. 
Information from the diary will be entered into the  eCRF.  
5.8 Prior  and Concomitant Therapy  
Use of all prior medications within 1 month prior to study drug administration will be 
recorded in the subject ’s eCRF.  The minimum requirement is that drug name and the dates 
of administration are recorded.  This will include all prescription drugs, herbal products, vitamins, minerals, and OTC medications.  Any changes in prior or concomitant medications will also be recorded in the subject ’s eCRF.  
Any concomitant medication deemed necessary for the well -being of the subject during the 
study may be given at the discretion of the Investigator after consideration of the clinical situation and the potential for masking symptoms of a more significant underlying event (Section 5.8.1) .  The Investigator is responsible for ensuring that details regarding 
concomitant medication use are recorded in the eCRF.  For each concomitant medication administered after admission to the CRU on Day -2 or Day - 1, as the case may be, the 
following details will be documented and recorded in the subject’ s eCRF: name of 
medication, dose administered, date and time of administration, and reason for medication use. 
Upon entering the study, each subject will be instructed about the importance of not taking any medication (including OTC medications) without consulting the Investigator. 
5.8.1 Permitted  Therapy  
Allowed medications include those typically prescribed to treat ADPKD, CKD and their complications, with th e exception of tolvaptan.  These include angiotensin II receptor 
blockers ( e.g., valsartan, candesartan, telmisartan, irbesartan)  and angiotensin -converting 
enzyme inhibitors (e.g., enalapril, lisinopril).   
Acetaminophen, at doses ≤ 1 g per day, is permitted for use any time during the study in 
subjects who usually take acetaminophen to control episodic pain.  Higher daily doses of acetaminophen may be allowed on a case- by-case basis upon the Investigator’s discretion 
and only in consultation with the Medical Monitor.  The use of acetaminophen at any dose is not permitted in subjects who cannot recall taking acetaminophen at least once in the prior 12 
months.   
Non-sedating antihistamines (other than loratadine) and decongestants may be permitted on 
an as -needed basis.  Low-dose aspirin (up to 325 mg per day) is permitted.   
Chronic use of other concomitant medications that are required to treat a medical condition 
may be permitted, unless otherwise prohibited (Sections 4.1.2 and 5.8.2), on a case -by-case 
basis upon the Investigator’s discretion in consultation with the Medical Monitor.  All 
medications should be stable for 1 month prior to dosing, allowing for minor adjust ments per 
the standard of care to treat medical conditions and avoiding, whenever possible, adjustments that will significantly impact serum creatinine levels.   The stability of certain drugs, such as 
insulin  and warfarin , should be based on the standard of care rather than on a stable dose.   
Palladio Biosciences  PA-102 Page 36 of 66 
 
21-Mar-2019  Confidenti al Information  Version 5  Lixivaptan has the potential to inhibit the metabolism of CYP3A4 and CYP2C8 substrates, 
including atorvastatin , simvastatin, and amlodipine. T herefore, care should be exercised 
when administering lixivaptan in combination with these substrates.   In order to minimize the 
potential for AEs due to drug- drug interactions,  prior to enrollment in the study, the 
Investigator, in consultation with the Medical Monitor, should consider potential dose adjustments or alternative therapeutic options that are not CYP3A4 or CYP2C8 substrates (e.g. rosuvastatin to replace simvastatin or atorvastatin) or that have a high therapeutic index.  If subjects are receiving simvastatin as background medication  and it is not possible to 
replace simvastatin with rosuvastatin, the dose of simvastatin should be decreased to < 20 mg daily in subjects who are administered the 50 mg BID dose of lixivaptan and < 10 mg daily in subjects who are administered the 200 mg BID dose of lixivaptan.  If amlodipine is needed for clinical care, the dose should not exceed 5 mg daily. 
5.8.2 Prohibited  Therapy  
Appropriate medications may need to be administered at the discretion of the Investigator as described in Section 5.8 and Section 5.8.1 if required for proper care of the patient.  However, subject s must abstain from taking certain prescription and  non-prescription drugs 
or supplements during the period prior to Day  1, and until after the final assessment on 
Day 35.   
The following medications are strictly prohibited for all subjects within 30 days prior to study drug administration  on Day 1 (or 5 half-lives, whichever is longer) and until after the 
final assessments on Day 35: 
• Treatment with tolvaptan or conivaptan; 
• Treatment with any investigational drug or device;  
• Treatment with somatostatin analogs (e.g. lanreotide, pasireotide, octreotide, etc.);  
• Treatment with mTOR kinase inhibitors (e.g. everolimus, sirolimus, etc.) ; 
• Treatment with diuretics . 
Hormonal contraception is not permitted for female subjects of child- bearing potential.  
The following medications are strictly prohibited for all subjects within 14 days prior to study drug administration on Day 1 (or 5 half-lives, whichever is longer) and until after the final PK assessment : 
• Treatment with strong or moderate CYP3A4 or CYP2C8 inhibitors, including 
aprepitant , boceprevir, clarithromycin, chloramphenicol (not eye drops), cimetidine, 
ciprofloxacin, clopidogrel, clotrimazole (if used orally), cobicistat and cobicistat-
containing products, crizotinib, cyclosporine, danazol, deferasirox , diltiazem, 
dronedarone, erythromycin, fluconazole, fluvoxamine, gemfibrozil, HIV protease inhibitors, imatinib, isoniazid, itraconazole, josamycin, ketoconazole, nefazodone, posaconazole, quinupristin/dalfopristin, ritonavir and ritonavir-containing products, telaprevir, teriflunomide, tofisopam, troleandomycin, verapamil, voriconazole; 
• Treatment with strong or moderate CYP3A4 or CYP2C8 inducers, including barbiturates, bosentan, carbamazepine, efavirenz, enzalutamide, etravirine, modafinil, 
Palladio Biosciences  PA-102 Page 37 of 66 
 
21-Mar-2019  Confidenti al Information  Version 5  mitotane, nevirapine, oxcarbazepine, phenytoin, pioglitazone, rifabutin, rifampin, St. 
John’ s wort . 
The following medications are prohibited for all subjects within 7 days prior to study drug administration on Day 1 (or 5 half-lives, whichever is longer) and until after the final PK assessment : 
• Treatment with weak CYP3A4  or CYP2C8 inhibitors, including, chlorzoxazone, 
cilostazol, fosaprepitant, istradefylline, ivacaftor, lomitapide, ranitidine, ranolazine, tacrolimus, ticagrelor , trimethoprim.  For weak CYP3A4 or CYP2C8 inhibitors, 
medications may be allowed in consultation with the Medical Monitor ; 
• Treat ment with weak CYP3A4  or CYP2C8 inducers, including armodafinil and 
rufinamide.  For weak CYP3A4 or CYP2C8 inducers , medications may be allowed in 
consultation with the Medical Monitor. 
The use of CYP3A4 or CYP2C8 substrates is not prohibited, however care should be exercised when administering lixivaptan in combination with these substrates ( Section 5.8.1) 
due to the potential for drug- drug interactions.   
5.9 Diet, Fluid, and Activity Control  
During confinement at the CRU, subjects will receive standardized meals ( breakfast, lunch, 
dinner, and sna ck) at scheduled times that do not conflict with other study -related activities.  
Meals or snacks may be provided to subjects per the Investigator’s discretion.  Patients will 
be advised to maintain their normal diet upon discharge from the CRU. 
During Day s -2 and -1 of CRU confinement, subjects should continue consuming their usual 
amount of fluids.  Due to the expected aquaretic effects of lixivaptan, subjects should be 
reminded to maintain adequate fluid intake and be mindful of their thirst status at ea ch study 
visit starting with Day 1 of CRU confinement.  Subjects should be instructed to replenish fluids with each void and aim to drink 4-5 liters of fluid per day, or as needed to maintain adequate hydration, while taking lixivaptan.  Additionally, subj ects will be instructed to drink 
1-2 glasses of fluid before bedtime, regardless of perceived thirst , and replenish fluids 
overnight with each episode of nocturia.  During CRU confinement, water consumption will be freely available to all subjects and dail y fluid intake will be recorded.  Fluid intake will 
not be recorded outside of the CRU.  The Investigator will assess ongoing fluid needs (e.g., by monitoring daily body weight, urine output, laboratory testing, etc.) as necessary in order to maintain adequate hydration of the subject throughout the study.  Special care must be taken if subjects are at an increased risk of water loss , e.g. in case of vomiting or diarrhea.  
Patients will refrain from c onsumption of grapefruit or Seville oranges (or their juices) from 
7 days prior to the first dose of study medication until after the final PK assessment.  Consumption of caffeinated beverages (coffee, tea, sodas, etc.) will be permitted  during the 
study, however subjects must be advised to limit their consumption to two caffeinated drinks (12-16 fl. oz. each) per day.  Energy drinks with caffeine are prohibited. 
Patients will be advised not to consume alcohol from 72 hours before admission to the CRU on Day -1 or Day - 2, as the case may be, until discharge from the CRU on Day 8, and for 72 
hours before the final end of study assessment.  
Palladio Biosciences  PA-102 Page 38 of 66 
 
21-Mar-2019  Confidenti al Information  Version 5  Subjects will refrain from strenuous exercise from 48 hours prior to Check- in (Day -1) and 
during the study through the final end of study assessment. 
Patients who are smokers will be allowed to smoke ≤  10 cigarettes per day during the study. 
Palladio Biosciences  PA-102 Page 39 of 66 
 
21-Mar-2019  Confidenti al Information  Version 5  6 STUDY ASSESSMENTS AND PROCEDURES  
Before performing any study procedures, all potential subject s will sign an ICF.  Subject s 
will have the opportunity to have any questions answered before signing the ICF.  The 
Investigator must address all questions raised by the subject . 
The study assessments to be performed at each visit and timepoint are specified in the study 
schedule of a ssessments (Table 12-1 ).  Assessment windows are presented in  Table 12-2.  
6.1 Safety and Tolerability Assessments 
The safety and tolerability of lixivaptan  will be assessed by evaluation of AEs, physical 
examinations, vital sign measurements, ECGs, clinical laboratory parameters ( hematology, 
clinical chemistry including liver function tests, and urinalysis), and the questionnaire for 
tolerability .  Additional safety assessments may be performed as needed at the discretion of 
the Investigator.  Safety assessments will be performed at scheduled intervals from Day  -2 
through the end of study assessment as presented in the study s chedule of a ssessments  
(Table 12-1 ).  Assessment windows are presented in  Table 12-2.  
6.1.1 Body Height, Weight, and BMI  
Body height (centimeters) and weigh t (kilograms) will be measured  to the nearest tenth , and 
BMI will be calculated (BMI  [kg/m2] = body weight [kg] / height2 [m2]).  Assessment 
windows are presented in Table 12-2.  
6.1.2 Physical Examinations and Medical History  
Complete  physical examinations will include, at a minimum, general appearance and 
assessment of the following systems: skin, head, ears, eyes, and throat, respiratory system, cardiovascular system, gastr ointestinal system, neurologic  system , blood and lymphatic 
systems, and the musculoskeletal system.  A licensed physician or qualified designee will 
conduct the examinations. 
Brief  physical examinations include, at a minimum, assessment of the following systems: 
skin, head, eyes , and throat, c hest and heart auscultation , abdominal examination, neurologic 
condition (i.e., alert and oriented x3; not including cranial nerves), and edema and hydration 
assessment.  A licensed physician or qualified designee will conduct the examinations. 
Physical examination s may be performed at various unscheduled time poi nts if deemed 
necessary by the I nvestigator.  Symptom- directed physical examinations will be performed as 
appropriate for subjects experiencing AEs.  
Medical history and demographic data, including initials , sex, age, race, and ethnicity will be 
recorded  at the timepoints  specified in the study schedule of assessments  (Table 12-1).  
6.1.3 Vital Sign Measurements 
Vital sign measurements will include systolic blood pressure, diastolic blood pressure, pulse rate, respiration rate, and body temperature and will be performed at the timepoints specified 
Palladio Biosciences  PA-102 Page 40 of 66 
 
21-Mar-2019  Confidenti al Information  Version 5  in the study schedule of assessments  (Table 12-1 ).  Assessment windows are presented in 
Table 12-2.  
Subject s will remain at rest in a seated  position for a minimum of 5 minutes before vital sign  
measurements are obtained .  For all subject s, blood pressure and pulse rate will be measured 
using an automated sphygmomanometer.  A confirmatory repeat vital sign  measu rement may 
be performed at the discretion of the I nvestigator.  If other procedures are scheduled at the 
same timepoint, vital signs  will be obtained first, before an ECG and/or blood draw. 
6.1.4 12-Lead Electrocardiograms 
Electrocardiogram  parameters of heart r ate, ventricular  rate, PR interval, QRS duration, QT 
interval (uncorrected), and QT interval corrected for heart rate according to Fridericia’ s 
formula ( QTcF ) will be performed at the timepoints specified  in the study schedule of 
assessments ( Table 12-1) .  Assessment windows are presented in Table 12-2. 
Electrocardiograms  will be obtained with the subject  remaining in a supine or semi -
recumbent  position following 5 minutes of rest.  A ll electrocardiograms  throughout the study 
for a given subject should be measured in the same position, i.e. either all in a supine position 
or all in a semi-recumbent position.  If other procedures are scheduled at the same timepoint, the ECG should be obtained after  vital sign  measurements and/or before the scheduled blood 
draw .   
For all subject s, ECGs will be reviewed, signed, and dated by the Investigator or a qualified 
designee.  The ECGs will be classified as being one of three categories:  normal, abnormal 
but not clinicall y significant (NCS ), or abnormal and CS.  All CS findings will be reported as 
AEs. 
6.1.5 Clinical Laboratory Tests  
Blood and urine specimens will be collected for the clinical laboratory ( hematology, clinical 
chemistry, and  urinalysis ), pregnancy tests (all female subjects) and FSH tests (if necessary 
for postmenopausal female subjects) at the timepoints specified in the study schedule of assessments ( Table 12-1) .  A confirmatory assessment should be obtained as soon as possible 
for any clinically  significant abnormal laboratory parameter.   Mild elevation s in serum 
creatinine or serum sodium are know n pharmacodynamic effects of vasopressin antagonists 
like lixivaptan , therefore confirmatory assessment s for serum creatinine and serum sodium 
will be at the Investigator's discretion .   
Assessment windows are presented in Table 12 -2.  Clinical laboratory parameters for analysis 
are presented in Table 6-1. 
Palladio Biosciences  PA-102 Page 41 of 66 
 
21-Mar-2019  Confidenti al Information  Version 5  Table 6-1 Clinical Laboratory Parameters  
Chemistry Panel  Hematology  Urinalysis  
Alanine aminotransferase * Hematocrit  pH 
Albumin  Hemoglobin  Specific gravity  
Alkaline phosphatase * Red blood cell count  Protein  
Aspartate aminotransferase * Quantitative platelet count  Glucose  
Bilirubin  Total and Direct*  White blood cell count  Ketones  
Blood urea nitrogen    with differential (total and %):  Bilirubin  
Calcium    Neutrophils  Blood  
Chloride    Lymphocytes  Nitrite  
CO 2   Monocytes  Urobilinogen  
Creatinine    Eosinophils  Leukocyte esterase  
Gamma -glutamyl transferase*    Basophils  Microscopic examination (if  
Glucose     positive blood, nitrite,  
Phosphorous  Other Tests    leukocyte esterase, or protein)  
Potassium  Urine or serum p regnancy test  Urea  
Protein    (female subject s) Creatinine  
Sodium  FSH ( if necessary for  Sodium  
Urea   postmenopausal female  subject s)  
Uric acid    
Abbreviations: CO 2 = carbon dioxide; FSH = follicle -stimulating hormone.  
*Liver function test ing 
6.1.6 MRI Assessment  
In order to investigate lixivaptan ’s pharmacodynamic effect on kidney and liver volume, 
patients will undergo a standardized abdominal MRI assessment without use of intravenous 
contrast for the determination of combined renal volume of both kidneys (total kidney volume or TKV) and liver volume (LV) at 3 timepoints as specified in  Table 12-1:  
1) at baseline (any time from Screening until CRU admis sion);   
2) immediately after completion of the 7 -day treatment period (Day 8 or 9); and  
3) at the final End of Study assessment  (Day 35 
± 2).   
Given the importance of performing the second MRI assessment within a short time interval after the last dose of study medication (PM dose on Day 7), it is recommended that all MRI assessments be scheduled for each subject at the time of the Screening visit.  Assessment 
windows are presented in Table 12-2.   
Occasionally, patients may be unable to continue into the study after completing their 
Screening visit and baseline MRI assessment (for example, due to changed personal circumstances or for not meet ing laboratory inclusion criteria ).  These patients may 
subsequently qualify for the study and be rescreened at a later time.  In this case, their prior baseline MRI assessment may be used instead of obtaining a new baseline MRI scan ; 
Palladio Biosciences  PA-102 Page 42 of 66 
 
21-Mar-2019  Confidenti al Information  Version 5  provided, however, that no more than 8 weeks have elapsed  from the time of the initial MRI 
assessment until admission into the CRU.    
The MRI acquisition protocol will be detailed in the study imagin g manual.  MRI images will 
be sent to a central reading facility for quality control and measurement of TKV and LV.  
Depending on technical feasibility, combined renal cyst volume (total cyst volume of both 
kidneys) and combined renal parenchyma volume (total parenchyma volume of both kidneys) may be determined  for a subset of subjects at a later date. 
In the absence of sonography or radiography evidence at the time of the Screening visit, the baseline MRI assessment could be used to confirm a subject’ s diagnosis of ADPKD 
according to modified Ravine criteria.  
Subjects with ferro -magnetic prostheses, aneurysm clips, severe claustrophobia or other 
contraindications or exclusions interfering with MRI measurements will be excused from this 
procedure, but may participate in the study providing that all other eligibi lity criteria are met.  
Investigator should seek MRI safety guidance from local MRI facility.  
6.1.7 Urine Osmolality and Specific Gravity  
Spot urine collections will be obtained at the timepoints specified in the study schedule of assessments ( Table 12-1).  Subjects will be asked to completely empty their bladders 15 
minutes prior to each scheduled spot urine collection, after which each subject will have 30 minutes to provide a spot urine specimen for the determination of urine osmolality and 
specific gravity .  The goal is to provide a spot urine sample within 30 minutes.  Subjects who 
will not be able provide a sample within the initial 30 minutes after voiding will be given an 
additional 30 minutes to do so and the different sampling time will be recorded .   
Spot urine samples will be used to construct the time course of urine osmolality and specific gravity upon dosing.  Urine osmolality measurements will be per formed  at the central 
laboratory, whereas t he determination of urine specific gravity will be performed in the CRU 
in two manners: using dipsticks provided by the Sponsor and using existing CRU equipment, 
where available.  
6.1.8 Questionnaire for Tolerability  
A questionnaire will be provided in the study reference manual that will assess how well patients tolerate aquaresis -associated events due to the planned lixivaptan  doses.  The 
questionnaire will be completed at 2 timepoints as specified in the study schedule of assessments ( Table 12-1). 
6.1.8.1  Sample Collections  
Instructions regarding the collection,  processing, and shipment of laboratory samples is 
detailed in a separate laboratory  manual .  All samples will be given a unique ide ntifier.  The 
exact clock time of dosing, as well as actual sample collection date and time will be entered on the eCRF. 
Palladio Biosciences  PA-102 Page 43 of 66 
 
21-Mar-2019  Confidenti al Information  Version 5  Blood samples for the PK analysis of lixivaptan  will be collected at the timepoints specified 
in the study schedule of assessments  (Table 12-1 ).  Assessment windows are presented in 
Table 12-2. 
6.1.9 Adverse Events  
6.1.9.1  Definitions  of Adverse Events  
The Investigator is responsible for reporting all AEs that are observed or reported during the 
study, regardless of their relationship to study drug or their clinical significance , as outlined 
in Section 6.1.9.2 below. 
An AE  is defined as any untoward medical occurrence in a subject enrolled into this study 
regardless of its causal relationship to study drug. A treatment- emergent AE ( TEAE) is defined  as any event not present before exposure to 
study drug or any event already present that worsens in either intensity or frequency after 
exposure to study drug. 
An SAE  is defined as any event that results in death, is immediately life threatening, requires  
in-subject  hospitalization or prolongation of existing hospitalization, results in persistent or 
significant disability/incapacity, or is a congenital anomaly/birth defect.  Important medical 
events  that may not result in death, be life threatening, or re quire hospitalization may be 
considered SAEs when, based upon appropriate medical judgment, they may jeopardize the 
subject  or may require medical or surgical intervention to prevent one of the outcomes listed 
in this definition.  
6.1.9.2  Eliciting and Documenting Adverse Events  and Serious Adverse 
Events  
AEs and SAEs that are related to stud y participation (e.g., protocol-mandated intervention) 
will be recorded from the time the subject  signs the ICF until the start of study treatment.  All 
other AEs and SAEs will be recorded from the start of study treatment until exit from the 
study.  Other changes in health or new symptoms occurring during the screening period will be recorded as medical history . 
At every study visit, subject s will be asked a standard nonlea ding question to elicit any 
medically related changes in their well -being .  They will also be asked if they have been 
hospitalized, had any accidents, used any new medications, or changed concomitant medication regimens (both prescription and over-the-counter  medications).  
In addition to subject  observations, A Es will be documented from any data collected that is 
deemed clinically significant by the Investigator (e.g., laboratory values, physical 
examination findings, vital signs, or ECG changes) or identified from review of other documents (e.g., subject  diaries) that are relevant to subject  safety.  
Palladio Biosciences  PA-102 Page 44 of 66 
 
21-Mar-2019  Confidenti al Information  Version 5  6.1.9.3  Reporting Adverse Events  
All A Es reported or observed during the study will be recorded on the AE page of the eCRF.  
Information to be collected includes drug treatment, dose, event term, time of onset, 
Investigator-specified assessment of severity and relationship to study drug, time of resolution of the event, seriousness, any required treatment or evaluations, and outcome.  Adverse events resulting from concurrent illnesses, reactions to concurrent illnesses, reactions to concurrent medications, or progression of disease states must also be reported.  All A Es will be followed to adequate resolution. 
Any medical condition that is present at the time that the subject  is screened but does not 
deteriorate should not be reported as an AE.  However, if it deteriorates at any time during the study, it should be recorded as an AE. 
Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or other 
safety assessments (e .g., ECGs, radiological scans, vital sign measurements), including those 
that worsen from b aseline, deemed  to be CS  in the medical and scien tific judgment of the 
Investigator are to be recorded as A Es or SAEs.  
However, any safety assessments that are associated with the underlying disease, unless judged by the Investigator  to be more severe than expected for the subject’s condition, are 
not to  be reported as A Es or SAEs.  
Any AE that meets SAE criteria (Section  6.1.9.1) must be reported to the Medical Monitor 
and Sponsor (or designee) immediately (i.e. within 24 hours) after the time site personnel first learn about the event.  Investigators should record a ll SAE details available , including 
investigator causality assessment,  on an Adverse Event eCRF and submit the report via the 
EDC system  within 24 hours of becoming aware of the event.  Notification of SAE entry will 
be generated and sent to Palladio Drug Safety and its designee by the EDC system. In the event the EDC system is unavailable, a completed SAE Report Form should be submitted to IQVIA drug safety via email at PHV_PA-102@quintiles.com  or via fax at 1-866-599-1342. 
If questions arise regarding SAE report submission, please contact the IQVIA Lifecycle Safety SAE hotline for assistance at 1 -866-599-1341.   
6.1.9.4  Assessment of Severity  
AEs should be graded as mild, moderate, severe, life-threatening, or death using the 
following definitions: 
• Mild (Grade 1): Awareness of signs or symptoms, but easily tolerated and of a minor irritant type, causing no loss of time from normal activities.  Symptoms do not require therapy or a medical evaluation; signs and symptoms are transient.  
• Moderate (Grade 2): Events introduce a low level of inconvenience or concern to the 
participant and may interfere with daily activities, but are usually improved by simple 
therapeutic measures; moderate experiences may cause some interference with functioning. 
Palladio Biosciences  PA-102 Page 45 of 66 
 
21-Mar-2019  Confidenti al Information  Version 5  • Severe (Grade 3): Events interrupt the participant ’s normal daily activities and 
generally require systemic drug therapy or other treatment; they are usually 
incapacitating.  
• Life-threatening (Grade 4): Events that place the participant  at immediate risk of 
death or are disabling. 
• Death (Grade 5): Events that result in death.  
Changes in the severity of an AE should be documented to allow an assessment of the duration of the event at each level of intensity to be performed.  Adverse events characterized 
as intermittent do not require documentation of onset and duration of each episode. 
6.1.9.5  Assessment of Causality  
The Investigator ’s assessment of causality must be provided for all AEs.  The causality is the 
determination of whether there exists a reasonable possibility that the study drug itself caused or contributed to an AE. 
If the final determination of causality is unknown and the Investigator does not know 
whether the study drug caused the event, then the event will be handled as “possibly related 
to study drug ” for reporting purposes.  If the Investigator’ s causality is “unknown, but not 
related to study drug ”, this should be clearly documented on study records. 
The relationship of an AE to the administration of the study drug will be assessed and recorded on the eCRF.  Terms used to describe the degree of causality between a study 
drug/investigational product and an AE are: definitely, probably, possibly, unlikely, or not related.   The best estimate at the time of reporting of the causal relationship between the 
experimental intervention and an AE and the degree of certainty about causality will be graded using the criteria specified in Table 6 -2. 
Table 6-2 Guideline for Assessment of Adverse Event Causality  
Relationship to Study Drug  Description  
Not Related  The AE is clearly due to extraneous causes (e.g., underlying disease, 
environment) or exposure to the investigational product has not occurred .  
Such events MUST have an alternative, definitive etiology documented in 
the subject's medical record.  
Unlikely Related  A potential relationship between study drug and the AE could exist (i.e., 
the possibility cannot be excluded), but the AE is most likely explained by causes other than the study drug (e .g., could readily have been produced by 
the subject’s clinical state or could have been due to environmental or other interventions).  
Possibly Related  The AE and administration of study drug are reasonably related in time and/or follow a known pattern of response, and the AE can be explained equally well by causes other than study drug (e.g., could readily have been 
produced by the subject’s clinical state or could have been due to 
environmental or other interventions).  
Palladio Biosciences  PA-102 Page 46 of 66 
 
21-Mar-2019  Confidenti al Information  Version 5  Probably Related  The AE and administration of study drug are reasonably related in time 
and/or follow a known pattern of response, and the AE is more likely 
explained by study drug than other causes.  
Definitely Related The AE and administration of study drug are related in time, and a direct 
association can be demonstrated (e.g., disappears or decreases with reduction in dose or cessation of drug/inves tigational product and recurs 
with re -exposure).  
6.1.9.6  Follow -Up of Subject s Reporting Adverse Events  
All AEs must be reported in detail on the appropriate page of the eCRF and followed to 
satisfactory resolution , until the Investigator deems the event to be chronic or not CS , or until 
the subject  is considered to be stable.  
6.2 Laboratory Analyses 
Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or other 
safety assessments (e .g., ECGs, radiological scans, vital sign measurements), including those 
that worsen from baseline, felt to be CS  in the medical and scientific judgment of the 
Investigator are to be recorded as AEs or SAEs.  
However, any safety assessments that are associated  with the underlying disease, unless 
judged by the Investigator  to be more severe than expected for the subject’s condition, are 
not to be reported as AEs or SAEs.  
6.3 Pregnancy  
Pregnancy is not regarded as an AE unless there is a suspicion that an investigational product may have interfered with the effectiveness of a contraceptive medication.  Any pregnancy that occurs during study participation must be reported using a clinical study pregnancy reporting form.  To ensure subject safety, each pregnancy must be reported within 24 hours of 
learning of its occurrence to the Medical Monitor and to IQVIA Lifecycle Safety on the 
paper pregnancy reporting form to PHV_PA-102@quintiles.com .  
The pregnancy must be followed-up to determine outcome (including spontaneous miscarriage, elective termination, normal birth, or congenital abnormality) and status of mother and child, even if the subject was discontinued from the study.  Pregnancy complications and terminations of pre gnancy will be reported as an SAE if SAE criteria are 
fulfilled.  Spontaneous miscarriages must be reported as an SAE. 
Any SAE occurring in association with a pregnancy, brought to the Investigator’ s attention 
after the subject has completed the study, and considered by the Investigator as possibly 
related to the study treatment, must be promptly reported to the Medical Monitor and the Sponsor. 
Palladio Biosciences  PA-102 Page 47 of 66 
 
21-Mar-2019  Confidenti al Information  Version 5  7 STATISTICAL AND ANALYTICAL PLAN 
The statistical and analytical plan for this study is summarized below.   Furt her details are 
provided separately in the Statistical Analysis Plan (SAP).  
7.1 Pharmacokinetic  Parameters  
The following PK parameters will be calculated using noncompartmental methods, whenever 
possible, based on lixivaptan  and lixivaptan  metabolite (WAY -141624, WAY -138451, and 
WAY -138758) concentrations, and at the timepoints shown in Table 12-1:  
PK Day 1 ( AM Dose)  
PK Parameter  Definition  
Cmax maximum observed plasma drug concentration  
tmax time to reach maximum plasma concentration  
AUC 0-t area under the concentration -time curve from time 0 until the last quantifiable 
concentration, calculated using the linear trapezoidal rule for increasing values, and 
the log trapezoidal rule for decreasing values  
AUC 0-inf area under the concentration -time curve extrapo lated to infinity, calculated as: 
AUC 0-inf = AUC 0-t + C t/λz 
Λz apparent terminal elimination rate constant  
t1/2 terminal elimination phase half -life, calculated as ln(2)/λz  
CL/F  total body clearance, calculated as Dose/AUC 0-inf (lixivaptan only)  
Vz/F  volume of distribution, calculated as CL/F/λz  (lixivaptan only)  
 
PK Day 1 ( PM Dose) – Study Day 1 - 2 
PK Parameter  Definition  
Cmax maximum observed plasma drug concentration  
tmax time to reach maximum plasma concentration  
AUC 0-t area under the concentration -time curve from time 0 until the last quantifiable 
concentration, calculated using the linear trapezoidal rule for increasing values, and 
the log trapezoidal rule for decreasing values  
 
Palladio Biosciences  PA-102 Page 48 of 66 
 
21-Mar-2019  Confidenti al Information  Version 5  Day 7 ( AM Dose ) 
PK Parameter  Definition  
Cmax maximum observed plasma drug concentration  
tmax time to reach maximum plasma concentration  
AUC 0-t area under the concentration -time curve from time 0 until the last quantifiable 
concentration, calculated using the linear trapezoidal rule for increasing values, and 
the log trapezoidal rule for decreasing values  
CL/F  total body clearance, calculated as Dose/AUC 0-last- (lixivaptan only)  
Vz/F  volume of distribution, calculated as CL/F/λz  (lixivaptan only)  
 
Day 7 ( PM Dose ) 
PK Parameter  Definition  
Cmax maximum observed plasma drug concentration  
tmax time to reach maximum plasma concentration  
AUC 0-14 area under the concentration -time curve from time 0 until 14 hours postdose  
AUC 0-t area under the concentration -time curve from time 0 until the last quantifiable 
concentration, calculated using the linear trapezoidal rule for increasing values, and 
the log trapezoidal rule for decreasing values  
Λz apparent terminal elimination rate constant  
t1/2 terminal elimination phase half -life, ca lculated as ln(2)/λz  
 Pharmacokinetic parameters will be calculated using validated software and  using actual 
sampling times.  The calculation of PK summary statistics will be performed using  validated 
software .   
Calculation of accumulation r atios (Day 7/Day 1), metabolite to parent ratios for each 
metabolite, an  assessment of dose proportionality, or additional calculations may be made as 
appropriate to fully characterize available data.  Additional details regarding the PK 
parameter calculat ions are presented in the SAP. 
7.2 Pharmacodynamic  Parameters  
The PD analysis will include assessments of urin e osmolality and urine output , total kidney 
volume, liver volume, plasma  copeptin, and s erum creatinin e in ADPKD subjects (see Table 
12-1) .  Pharmacodynamic data will be listed and summarized as detailed in the SAP.  
7.3 Safety Variables  
The safety analysis will include c linical laboratory findings (hematology, clinical chemistry, 
and urinalysis), 12- lead ECGs,  vital signs , physical examination findings , assessments of 
AEs and the questionnaire of tolerability .  Safety data will be listed and summarized as 
detailed in the SAP.  
Palladio Biosciences  PA-102 Page 49 of 66 
 
21-Mar-2019  Confidenti al Information  Version 5  7.4 Sample Size Calculations  
Calculations were performed assuming a coefficient of variation (CV) of 0.30 and 0.41 for 
lixivaptan C max and AUC, respectively.  Assuming lognormal distribution, this implies that 
the variances for the logarithm of C max and AUC are 0.086 and 0.155, respectively.  Under 
these assumptions and a random sample of 8 observations, the probability is 0.90 that the point estimate of the population central value (observed geometric mean) for lixivaptan C
max 
and AUC will be within (84.3%, 118.6%) and (79.5%, 125.7%) of the population central value (the median), respectively.  
From the perspective of tolerability assessment for multiple dose regimens, for the true population incidence rates of 0.10, 0.20, 0.30, 0.40 and 0.50 for a given AE, the probabilities 
that the AE would not be observed in a group of 8 subjects administered l ixivaptan are given 
in Table 7-1. 
Table 7-1 Probability of Not Observing an Adverse Event for Various True Incidence 
Rates  
True Incidence Rate  Probability of Not Observing an  
AE in Group of 8 Subjects  
0.1 0.43 
0.2 0.168  
0.3 0.058  
0.4 0.017  
0.5 0.004  
Abbreviation: AE = adverse event.  
7.5 Analysis Sets 
The following analysis sets  will be used in the statistical analyses.  
Safety Analysis Set : The Safety Analysis Set  will consist of all subject s who receive any 
study drug.  This analysis set will be used for the safety analyses and for summarization of 
baseline/demographic characteristics . 
Pharmacokinetic  Analysis Set : The PK Analysis Set  will consist of all subject s who undergo 
plasma PK sampling and have evaluable PK assay results .  This analysis set  will be used for 
the PK  analysis an d for summarization of concentration/parameter data. 
Pharmacodynamic  Analysis Set : The PD Analysis Set  will consist of all subject s who receive 
study drug and have at least 1 postdose PD assessments of urine osmolality .  This analysis set  
will be used for the PD analysis and for summarization of PD biomarker data. 
7.6 Description of Subgroups to be Analyzed  
No subgroup analyses are planned. 
Palladio Biosciences  PA-102 Page 50 of 66 
 
21-Mar-2019  Confidenti al Information  Version 5  7.7 Statistical Analysis Methodology 
Statistical analysis will be performed using SAS® software Version 9.2 or higher .  All 
continuous variables will be summarized using the following descriptive statistics: number of 
non-missing observations (n), mean, standard deviation (SD), median, minimum, and maximum.  Categorical variables will be summarized using the following descriptive statistics: frequency counts and percentages.  All data will be listed in data listings.   Missing 
data will not be imputed but will be analyzed as missing . 
Further details of the statistical analyses, methods, and data conventions are described i n the 
SAP.  The SAP may modify the plans outlined in the protocol; however, any major modifications of the primary analysis will also be reflected in a protocol amendment.  Additional statistical analyses other than those described in this section may be p erformed if 
deemed appropriate in the plan. 
7.7.1 Pharmacokinetic Analysis  
The parameters describing the PK will be derived from plasma concentrations  of lixivaptan 
and its metabolites and actual sample draw times using noncompartmental analysis.  For 
summary of  plasma and urine concentrations, concentrations below the limit of quantification 
(BLQ) will be treated as zero for the calculation of all summary statistics except for the calculation of geometric mean and CV% of geometric mean, where they are treated as  
missing . 
Plasma concentration data for lixivaptan and its metabolites will also be displayed graphically on linear and semi- logarithmic scales.  The following plots will be presented for 
the concentration -time data: 
• Individual subject plasma concentration  profile versus time, stratified by renal 
function group. 
• Arithmetic -mean concentration (±SD) versus time, stratified by renal function group. 
Additional details regarding the PK parameter calculations are presented in the SAP. 
7.7.2 Pharmacodynamic Analyses  
The change from baseline in urine osmolality, serum creatinine, plasma  copeptin, TKV and 
LV after multiple doses of lixivaptan  will be summarized by renal function group (CDK1/2 
and CDK3), and at each scheduled time point using des criptive statistics (n, mean, SD, 
median, m inimum, and m aximum).  
Except for the case of urine osmolality, t he baseline value is the last value observed prior to 
first administration of study drug and any values  after first administration of  study drug are 
regarded as post -baseline values .  The change -from -baseline variables  will be calculated as 
the post- baseline val ue minus the value at baseline. 
For urine osmolality assessments, t he baseline value for each time point after first 
administration of  study drug is the value observed at the corresponding time point on Day -1 
(or Day 1 for the AM predose assessment only).  A ny values  after first administration of  
Palladio Biosciences  PA-102 Page 51 of 66 
 
21-Mar-2019  Confidenti al Information  Version 5  study drug are regarded as post- baseline values .  The change- from -baseline variables  will be 
calculated as the post -baseline val ue minus the value at baseline.  The number of subjects 
who show suppressed urine osmolality, defined as spot urine osmolality < 300 mOsm/kg for 
24h, on Day 1 (AM predose) compared with Day 8 (AM predos e) will be determined.   
7.7.3 Safety Analyses  
Clinical Laboratory Tests  
All laboratory data will be summarized by renal function group and at each scheduled timepoint using descriptive statistics (n, mean, SD, median, m inimum, and m aximum).  
The baseline value is the last value observed prior to first administration of study drug and any information taken after first administration of study drug is regarded as post baseline information.  The change -from -baseline variables  will be calculated as  the post -baseline 
value minus the value at baseline.   Change from baseline on continuous data will be 
summarized using descriptive statistics at each scheduled time point by renal function group.  For categorical data, change- from -baseline will be summarized using frequency and 
proportion at each scheduled timepoint by renal function group. 
Individual data listings of laboratory results will be presented for each subject .  Values 
outside of the laboratory's reference range (i. e., those with low or high val ues) wi ll be 
flagged in the laboratory listings.  
For all continuous laboratory variables, a shift table comparing the baseline value (normal, 
low, and high) to last observation on treatment will be presented. 
For urinalysis, a shift table comparing the bas eline value to the maximum value will be 
presented by renal function group (using number of subjects with results of negative, trace, or 
positive). 
ECGs  
A listing will be provided for Investigator- identified ECG abnormalities  from safety ECGs .  
Overall evaluation of safety ECG s will be summarized by renal function group using 
frequency counts and percentage of subject s as normal or abnormal, and the relevance of the 
abnormality will be summarized by CS  or NCS . 
In addition, a summary shift table comparing baseline interpretation (normal, abnormal - NCS, abnormal - CS) to the Investigator interpretation at each time point will also be presented.  
Continuous ECG parameters including heart rate, ventricular rate, PR interval, QRS duration, 
QT interval ( uncorrected), and QTcF interval will be summarized for renal function group 
and over each scheduled timepoint in terms of absolute values using descriptive statistics (n, mean, SD, median, m inimum, and m aximum).  
Palladio Biosciences  PA-102 Page 52 of 66 
 
21-Mar-2019  Confidenti al Information  Version 5  Vital Signs  
Changes from baseline in vital signs at each scheduled timepoint will be summarized by 
renal function group for the Safety Analysis Set  using descriptive statistics (n, mean, SD, 
median, m inimum, and m aximum).  The baseline value is defined as the last value observed 
prior to first administration of study drug.  The change from baseline is defined as the 
post- baseline value minus the baseline value.  There will not be any imputation for missing 
values.   All vital sign data will be listed individuall y by each subject  based on the Safety 
Analysis Set . 
Physical Examination s 
Changes in baseline in physical examination findings  (Normal, Abnormal -NCS,  
Abnormal- CS) will be summarized using counts and percentages for renal function group 
and will also be listed individually for each schedule d time point. 
Adverse Events  
An overall summary of the number and percentage of subject s in each category will be 
presented, as will an overall summary of the number of events in each category.  The number 
and percentage of subject s reporting AEs in each category above will be summarized by  renal 
function group according to the system organ class (SOC) and preferred term (PT) assigned to the event using MedDRA. 
All AE data will be listed for all subject s.  Bo th the Investigator’s verbatim terms and the 
MedDRA preferred terms will be listed for each subject .  Listings will also include the SAEs , 
start and end time and date of AEs , relationship to study drug, severity, and action taken for 
the AEs.   A summary of  deaths ( for all deaths, AE outcome, not AE term, is death) will be 
provided by number and percentage of subject s by renal function group. 
Questionnaire for Tolerability  
Tolerability data obtained from the questionnaire will be listed and summarized as detailed in 
the SAP.  
7.7.4 Other Analyses 
Listings will be provided for subject disposition, demographics, medical history, prior and concomitant medications, and summary tables will be prepared for disposition and demographics. 
7.8 Data Quality Assurance  
Standard operating procedures are available for all activities performed at the study sites relevant to the quality of this study.  Designated study site personnel will be responsible for maintaining quality assurance and quality control to ensur e that the study conduct as well as 
data collection and documentation are performed in compliance with the study protocol, GCP requirements, and applicable regulatory requirements. 
Palladio Biosciences  PA-102 Page 53 of 66 
 
21-Mar-2019  Confidenti al Information  Version 5  All clinical data will undergo source document verification by the Clinical Research 
Associate and data review by Data Management prior to database lock.  Programmed edit checks are also implemented to check for missing data, data inconsistencies, data ranges, etc.  Corrections are made prior to database lock.  Electronic CRFs can be printed directly from the database.  Each eCRF will be reviewed and signed electronically by the Investigator . 
7.8.1 Data Management  
As part of the responsibilities assumed by participating in the study, the Investigator agrees to maintain adequate case his tories for the subjects treated as part of the research under this 
protocol.  The Investigator agrees to maintain accurate eCRFs and source documentation as 
part of the case histories.  Thes e source documents may include laboratory reports, ECG s, 
etc. 
Investigative site personnel will enter subject  data into eCRFs using the Oracle Clinical 
Remote Data Capture program .  The analysis data sets will be a combination of these data 
and data from other sources (e.g., laboratory data)  and follow Clinical Data Inte rchange 
Standards Consortium ( CDISC ) standard . 
Clinical data management will be performed in accordance with applicable IQVIA standards 
and data cleaning procedures to ensure the integrity of the data, e.g.  removing errors and 
inconsistencies in the data.  Adverse events and concomitant medication terms will be coded using the MedDRA and World Health Organization Drug Dictionaries, respectively . 
After database lock, each study site will receive all site- specific eCRF data for the study, 
including full discrepancy and audit history.  Additionally, a copy of all of the study site’ s 
data from the study will be created and sent to the Sponsor for storage.  IQVIA will maintain 
a duplicate copy for their records.  In all cases, subject initials will not be collected or transmitted to the Sponsor. 
Palladio Biosciences  PA-102 Page 54 of 66 
 
21-Mar-2019  Confidenti al Information  Version 5  8 ETHICS 
8.1 Institutional Review Board  
Federal regulations and the ICH guidelines require that ap proval be obtained from an IRB 
before participation of human subject s in research studies.  Before study onset, the protocol, 
informed consent, advertisements to be used for the recruitment of study subject s, and any 
other written information regarding this study to be provided to the subject  or the subject ’s 
legal guardian must be approved by the IRB.  Documentation of all IRB approvals and of the 
IRB compliance with ICH harmonized tripartite guideline E6  (R1): GCP will be maintained 
by the site and will be available for review by the Sponsor or its designee. 
All IRB  approvals should be signed by the IRB chairman or designee and must identify the 
IRB name and address, the clinical protocol by title or protocol number or both, and the date approval or a favorable opinion was granted. 
The Investigator is responsible for providing written summaries of the progress and status of 
the study at intervals not exceeding 1  year or otherwise specified by the IRB.  The 
Investigator must promptly supply the Sponsor or its designee , the IRB, and , where 
applicable, the institution,  with written reports on any changes significantly affecting the 
conduct of the study or increasing the risk to subject s. 
8.2 Ethical Conduct of the Study  
The study will be performed in accordance with the ethical principles that have their origin in 
the Declaration of Helsinki, IC H GCP , and all applicable regulations. 
8.3 Subject  Information and Consent  
A written informed consent in compliance with US Title  21 Code of Federal Regulations 
(CFR) Part  50 shall be obtained from each subject before entering the study or performing 
any unusual or non-routine procedure that involves risk to the subject .  An informed consent 
template may be provided by the Sponsor to investigative sites.  If any institution -specific 
modifications to study -related procedures are proposed or made by the site, the consent 
should be reviewed by the Sponsor or its designee or both before IRB submission.  Once reviewed, the consent will be submitted by the Investigator  to his or her IRB for review and 
approval before the start of the study.  If the ICF is revised during the course of the study, all active participating subjects must sign the revised form. 
Before recruitment and enrollment, each prospective subject  or his or her legal guardian will 
be given a full explanation of the study and be allowed to read the approved ICF.  Once the 
Investigator is assured that the subject /legal guardian understands the implications of 
participating in the study, the subject /legal guardian will be asked to give consent to 
participate in the study by signing the ICF.  
The Investigator shall retain the signed original ICF(s) and give a copy of the signed original 
form to the subject  or legal guardian. 
Palladio Biosciences  PA-102 Page 55 of 66 
 
21-Mar-2019  Confidenti al Information  Version 5  9 INVESTIGATOR’S OBLIGATIONS  
The following administrative items are meant to guide the Investigator in the conduct of the 
study but may be subject to change based on industry and government standard operating 
procedures, working practice documents, or guidelines.  Changes will be reported to the IRB 
but will not result in protocol amendments. 
9.1 Confidentiality  
All laboratory specimens, evaluation forms, reports, and other records will be identified in a manner designed to maintain subject  confidentiality.  All records will be kept in  a secure 
storage area with limited access.  Clinical information will not be released without the written permission of the subject  (or the subject’ s legal guardian), except as necessary for 
monitoring and auditing by the Sponsor, its designee, the FDA, or the IRB.  
The Investigator and all employees and coworkers involved with this study may not disclose 
or use for any purpose other than performance of the study any data, record, or other unpublished, confidential information disclosed to those individuals for the purpose of the study.  Prior written agreement from the Sponsor or its designee must be obtained for the disclosure of any said confidential information to other parties. 
9.2 Financial Disclosure and Obligations  
Investigators are required to provide f inancial disclosure information to allow the Sponsor to 
submit the complete and accurate certification or disclosu re statements required under 
21 CFR  54.  In addition, the Investigator must provide to the Sponsor a commitment to 
promptly update this information if any relevant changes occur during the course of the investigation and for 1 year following the completion of the study. 
Neither the Sponsor nor IQVIA is financially responsible for further testing  or treatment of 
any medical condition that may be detected during the screening process.  In addition, in the 
absence of specific arrangements, neither the Sponsor nor IQVIA is financially responsible 
for further treatment of the subject ’s disease.  
9.3 Investigator Documentation  
Before  beginning the study, the Investigator will be asked to comply with ICH E6 (R1) 
Section  8.2 and Title  21 of the CFR by providing the following essential documents, 
including but not limited to: 
• IRB approval 
• Original signed Investigator agreement page of the protocol 
• Form FDA 1572, fully executed, and all updates on a new fully executed Form FDA 1572 
• Curriculum vitae  for the Investigator and each S ub-Investigator listed on Form 
FDA  1572 
Palladio Biosciences  PA-102 Page 56 of 66 
 
21-Mar-2019  Confidenti al Information  Version 5  • Financial disclosure information to allow the Sponsor to submit complete and 
accurate certification or disclosure statements required under 21  CFR  54.  In addition, 
the Investigators must provide to the Sponsor a commitment to promptly update this 
information if any relevant changes occur during the course of the investigation and for 1  year after the completion of the study. 
• IRB-approved informed consent, samples of site advertisements for recruitment for 
this study, and any other written information regarding this study that is to be provided to the subject  or legal guardian, and 
• Laboratory certifications and normal ranges for any local laboratories used by the 
site, in accordance with 42  CFR  493 
9.4 Study Conduct  
The Investigator agrees that the study will be conducted according to the principles of ICH 
E6 (R1).  The Investigator will conduct all aspects of this study in accordance with all 
national, state, and local laws or regulations.  Study information from this protocol will be 
posted on publicly available clinical trial registers before enrollment of subje cts begins. 
9.5 Adherence to Protocol  
The Investigator agrees to conduct the study as outlined in this protocol in accordance with 
ICH E6  (R1) and all applicable guidelines and regulations. 
9.6 Adverse Events  and Study Report Requirements  
By participating in this study the Investigator agrees to submit reports of SAEs  according to 
the time line and method outlined in the protocol.  In addition, the Investigator agrees to submit annual reports to the study site  IRB as appropriate.  
9.7 Investigator ’s Final Report  
Upon completion of the study, the Investigator, where applicable, should inform the institution; the Investigator/institution should provide the IRB with a summary of the study’ s 
outcome and the Sponsor and regulatory authority with any reports required. 
9.8 Records Retention  
Essential documents should be retained until at least 2 years after the last approval of a 
marketing application in an ICH region and until there are no pending or contemplated 
marketing applications  in an ICH region, or at least 2 years have elapsed since the formal 
discontinuation of clinical development of the study drug .  These documents should be 
retained for a longer period, however, if required by the applicable regulatory requirements 
or by an agreement with the Sponsor.  It is the responsibility of the Sponsor to inform the 
Investigator/institution as to when these documents no longer need to be retained. 
Palladio Biosciences  PA-102 Page 57 of 66 
 
21-Mar-2019  Confidenti al Information  Version 5  9.9 Publications  
After completion of the study, the data may be considered for reporting at a scientific 
meeting or for publication in a scientific journal.  In these cases, the Sponsor will be 
responsible for these activities and will work with the Investigators to determine how the manuscript is written and edited, the number and order of authors, the publication to which it will be submitted, and other related issues.  The Sponsor has final approval authority over all 
such issues.  
Data are the property of the Sponsor and cannot be published without prior authorization from the Sponsor, but data and publication thereof will not be unduly withheld. 
Palladio Biosciences  PA-102 Page 58 of 66 
 
21-Mar-2019  Confidenti al Information  Version 5  10 STUDY MANAGEMENT  
10.1 Monitoring  
10.1.1  Monitoring of the Study  
The clinical monitor and/or designee, as a representative of the Sponsor, has the obligation to 
follow the study closely.  In doing so, the monitor will visit the Investigator and study site at 
periodic intervals, in addition to maintaining necessary telephone and letter contact.  The 
monitor will maintain current personal knowledge of the study through observation, review 
of study records and source documentation, and discussion of the conduct of the study with the Investigator and personnel. 
All aspects of the study will be caref ully monitored, by the Sponsor or its designee, for 
compliance with applicable government regulation with respect to current GCP and current standard operating procedures. 
10.1.2  Inspection of Records  
Investigators and institutions involved in the study will perm it study-related monitoring, 
audits, IRB review, and regulatory inspections by providing direct access to all study records.  In the event of an audit, the Investigator agrees to allow the Sponsor , representatives of the 
Sponsor, or a regulatory agency (e.g. FDA or other regulatory agency) access to all study 
records.  
The Investigator should promptly notify the Sponsor and IQVIA  of any audits scheduled by 
any regulatory authorities and promptly forward copies of any audit reports received to the Sponsor. 
10.2 Management of Protocol Amendments and Deviations  
10.2.1  Modification of the Protocol  
Any changes in this research activity, except those necessary to remove an apparent, immediate hazard to the subject , must be reviewed and approved by the Sponsor or its 
designee.  Amendments to the protocol must be submitted in writing to the Investigator’ s 
IRB for approval before subject s can be en rolled into an amended protocol, and before the 
changes can be implemented.  
10.2.2  Protocol Deviations 
The Investigator or designee must document and explain in the subject ’s source 
documentation any deviation from the approved protocol.  The Investigator may implement a 
deviation from, or a change of, the protocol to eliminate an immediate hazard to study subject s without prior IRB approval.  As soon as possible after such an occurrence, the 
implemented deviation or change, the reasons for it, and any proposed protocol amendments 
Palladio Biosciences  PA-102 Page 59 of 66 
 
21-Mar-2019  Confidenti al Information  Version 5  should be submitted to the IRB for review and approval, to the Sponsor for agreement, and to 
the regulatory authorities, if required. 
A protocol deviation is defined as an unintended or unanticipated departure from the 
procedures or processes approved by the Sponsor and the IRB and agreed to by the Investigator.  A major  deviation occurs when there is no t adherence to t he protocol by the 
subject  or Investigator that results in a significant,  additional risk to the subject .  Major  
deviations can include no t adher ing to inclusion or exclusion criteria , enrollment of the 
subject  without prior Sponsor approval, or not adher ing to FDA regulations or ICH GCP 
guidelines, and will lead to the subject  being withdrawn from the study ( Section  1). 
Protocol deviations will be documented by the clinical monitor throughout the course of monitoring visits.  Investigator s will be notified in writing by the monitor of deviations.   The 
IRB should be notified of all protocol deviations in a timely manner. 
10.3 Study Termination  
Although the Sponsor has every intention of completing the study, the Sponsor reserves the right to discontinue the study at any time for clinical or administrative reasons . 
The end of the study is defined as the date on which the last subject  completes the final end 
of study assessment . 
10.4 Final Report  
Whether the study is completed or prematurely terminated, the Sponsor will ensure that the clinical study report is  prepared and provided to the regulatory agency as required by the 
applicable regulatory requirement(s).   The Sponsor will also ensure  that the clinical study 
report  in marketing applications meet the standards of the ICH harmonized tripartite 
guideline E3: Structure and content of clinical study r eports. 
Where required by applicable regulatory requirements, an Investigator signatory will be identified for the approval of the clinical study report.  The Investigator will be provided 
reasonable access to statistical tables, figures, and relevant reports and will have the opportunity to review the complete study results. 
Upon completion of the clinical study report, the Sponsor will provide the Investigator with 
the fu ll summary of the study results.   The Investigator is encouraged to share the summary 
results with the study subjects, as appropriate.   The s tudy results will be posted on publicly 
available clinical trial registers.  
Palladio Biosciences  PA-102 Page 60 of 66 
 
21-Mar-2019  Confidenti al Information  Version 5  11 REFERENCE LIST  
1. Chan PS, Coupet J, Park HC, Lai F, Hartupee, D, Cervoni P, Dusza JP, Albright JD, 
Ru X, Mazandarani H, Tanikella T, Shepherd C, Ochalski L, Bailey T, Lock YYW, 
Ning X, Taylor JR, Spinelli W.  1998.  VPA-985, a nonpeptide orally active and selective vasopressin V
2 receptor antagon ist.  Adv Exp Med Biol. 449: 439-443. 
2. Chebib FT, Sussman CR, Wang X, Harris PC, Torres VE.  2015.  Vasopressin and disruption of calcium signaling in polycystic kidney disease.  Nat Rev Nephrol. 11(8):451-464. 
3. Antignac C, Calvet JP, Germino GG, Grantham JJ, Guay-Woodford LM, Harris PC, Hildebrandt F, Peters DJM, Somlo S, Torres VE, Walz G, Zhou J, Yu ASL.  2015.  The Future of Polycystic Kidney Disease Research — As Seen By the 12 Kaplan Awardees.  J Am Soc Nephrol (26): 2081-2095. 
4. Chapman AB, Devuyst O,  Eckardt K -U, Gansevoort RT, Harris T, Horie S, Kasiske 
BL, Odland D, Pei YP, Perrone RD, Pirson Y, Schrier RW, Torra R, Torres VE, 
Watnick T, Wheeler, DC .  2015.  Autosomal-dominant polycystic kidney disease 
(ADPKD): executive summary from a Kid ney Disease: Improving Global Outcomes 
(KDIGO) Controversies Conference.  Kidney Int. 88(1): 17-27 
5. Hogan MC, Abebe K, Torres VE, Chapman AB, Bae KT, Tao C, Sun H, Perrone RD, 
Steinman TI, Braun W, Winklhofer FT, Miskulin DC, Rahbari-Oskoui F, Brosnahan G, Masoumi A, Karpov IO, Spillane S, Flessner M, Moore CG, Schrier RW.  2015.  
Liver involvement in early autosomal dominant polycystic kidney disease.  Clin 
Gastroenterol Hepatol. 13(1): 155–164. 
6. Belibi FA, Reif G, Gail R, Wallace DP, Yamaguchi T, Olsen L, L i H, Helmkamp 
GM, Grantham, JJ.  2004.  Cyclic AMP promotes growth and secretion in human 
polycystic kidney epithelial cells.  Kidney Int. 66(3):964-973. 
7. Torres VE.  2005.  Vasopressin antagonists in polycystic kidney disease.  Kidney Int. 68(5):2405-2418. 
8. Wang X, Wu Y, Ward CJ, Harris PC, Torres VE.  2008.  Vasopressin directly regulates cyst growth in polycystic kidney disease.  J Am Soc Nephrol. 2008 Jan; 19(1): 102–108. 
9. Gattone II VH, Wang X, Harris PC, Torres VE .  2003.  Inhibition of renal cystic 
disease development and progression by a vasopressin V
2 receptor antagonist.  Nat 
Med. 9(10): 1323-1326. 
10. Wang X, Gattone V, 2nd, Harris PC, Torres VE.  2005.  Effectiveness of vasopressin V
2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease 
development in the PCK rat.  J Am Soc Nephrol. 16(4):846-851. 
Palladio Biosciences  PA-102 Page 61 of 66 
 
21-Mar-2019  Confidenti al Information  Version 5  11. Boertien WE, Meijer E, Zittema D, van Dijk MA, Rabelink TJ, Breuning MH, Struck 
J, Bakken SJL, Peters DJM, de Jong PE, Gansevoort RT.  2012.  Copeptin, a 
surrogate marker for vasopressin, is associated with kidney function decline in subjects with autosomal dominant polycystic kidney disease.  Nephrol Dial Transplant 27: 4131–4137. 
12. Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Hi gashihara E, 
Perrone RD, Krasa HB, Ouyang J, Czerwiec FS; TEMPO 3:4 Trial Investigators.  
2012.  Tolvaptan in patients with autosomal dominant polycystic kidney disease.  N 
Engl J Med. 367(25):2407-2418. 
13. Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Dandurand A, 
Ouyang J, Czerwiec FS, Blais JD; TEMPO 4:4 Trial Investigators.  2017a.  
Multicenter, open- label, extension trial to evaluate the long -term efficacy and safety 
of early versus delayed treatment with tolvaptan in autosomal dominant pol ycystic 
kidney disease: the TEMPO 4:4 Trial.  Nephrol Dial Transplant. 32(7):1262. 
14. Devuyst O, Chapman AB, Gansevoort RT, Higashihara E, Perrone RD, Torres VE, Blais JD, Zhou W, Ouyang J, Czerwiec FS.  2017.  Urine osmolality, response to 
tolvaptan, and outcome in autosomal dominant polycystic kidney disease: results 
from the TEMPO 3:4 trial.  J Am Soc Nephrol. 28(5):1592-1602. 
15. Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Koch G, Ouyang 
J, McQuade RD, Blais JD, Czerwiec FS , Sergeyeva O.  2017.  Tolvaptan in later-
stage autosomal dominant polycystic kidney disease.  N Engl J Med. 377:1930-1942. 
16. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek 
JW, Eggers P, Van Lente F, Greene T, Coresh J.  2009.  A New Equation to Est imate 
Glomerular Filtration Rate .  Ann Intern Med. 150:604-612 
Palladio Biosciences  PA-102 Page 62 of 66 
 
21-Mar-2019  Confidenti al Information  Version 5  12 APPENDICES  
12.1 Appendix  1: Chronic Kidney Disease  Classification  Criteria 
This study uses the 2009 CKD -EPI creatinine equation ,16 which is recommended by the 
KDIGO Clinical Practice Guidelines for Management of Chronic Kidney Disease . 
The CKD -EPI equation  is: 
𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒 =141 ×  𝑚𝑚𝑖𝑖𝑖𝑖�𝑆𝑆𝑆𝑆𝑆𝑆
κ, 1�α
×max�𝑆𝑆𝑆𝑆𝑆𝑆
κ, 1�−1.209
× 0.993Age× 1.018  (if female )× 1. 159 ( if black),   
where Scr  is serum creatinine, κ is 0.7 for females and 0.9 for males, α is -0.329 for females 
and - 0.411 for males, min indicates the minimum of Scr/ κ or 1, and max indicates the 
maximum of Scr/κ or 1. 
 
 
12.2 Appendix  2: Schedule of Assessments  
 
Palladio Biosciences PA -102 Page 63 of 66 
 
21-Mar-2019 Confidential Information  Version 5  Table 12-1 Schedule of Assessments  
Visit type:  Screening17 Admit17 In-
CRU  In-
CRU  Discharge 
after AM 
Assessments   PK 
Visit 
in AM   PK Visit  
in AM;  
Admit for 
PM dose  In-
CRU  Discharge 
after PK 
Collection and 
Assessments  PK 
Collection18 End of 
Study 
Visit  
              
Procedure : Study Day:  -44 to -3 
or -2 -2 or -1  -1 1 2 3 4 5 6 7 8 9-11 35 ±2 
Informed Consent  X             
Demographics  X             
Medical History  X             
Serum/Urine P regnancy  Test1,2 X X           X 
FSH3 X             
Height/Weight/BMI  X            X 
Inclusion/Exclusion  X             
Previous Medications1 X X            
Concomitant Medications4 X  X X X  X  X X X X X 
Clinical Lab Evaluations5 X  X X X     X X  X 
Serum  Creatinine6 X  X X X     X X  X 
Electrocardiogram7 X   X       X   
Vital Signs8 X  X X X  X  X X X  X 
Physical Examinations1,9 X X         X  X 
Adverse Events10 X  
Daily Fluid Intake11   X X X 
(AM only)      X X 
(AM only)    
Administer Dose in -CRU12    AM 
PM AM  AM  AM 
PM AM 
PM    
Self-Administer Dose12     PM AM 
PM PM AM 
PM      
PK Blood Samples13    X X  X  X X X X  
Urine Osmolality14   X X X     X X   
Daily Urine Output15   X X X 
(AM only)      X X 
(AM only)    
Tolerability Questionnaire      X     X    
Plasma Copeptin16   X  X     X   X 
TKV and LV (by MRI)   X       X   X 
Palladio Biosciences PA -102 Page 64 of 66 
 
21-Mar-2019 Confidential Information  Version 5  Abbreviations: BMI= body mass index, CRU = clinical research unit, EOS = end of study, FSH = follicle -stimulating hormone, MRI = magnetic resonance 
imaging, PK = pharmacokinetic, Preg.   = pregnancy, TKV = total kidney  volume, LV  = liver volume.   
 
1 Assessments will be performed on Day -1 or Day -2 for subjects admitted to CRU on Day -2.  
2 Serum pregnancy test to be performed at Screening; Urine pregnancy test to be performed at Day - 2 or Day -1 and at End of Study .  
3 Postmenopausal subject s with a urine pregnancy result outside the post -meno pausal range or an indeterminate pregnancy test will undergo additional testing 
with FSH  if necessary based on Investigator discretion  to confirm postmenopausal status prior to study enrollment.  
4 Includes over the counter medications . 
5 Clinical labs: hematology, clinical chemistry (including liver function), and urinalysis at approximately the same time of day (in the  morning and , on dosing 
days, before the lixivaptan dose).  The list of analytes is shown in Table 6-1. Lab tests  that need to be repeated during Screening may be obtained through the 
services of an at -home nursing service provided by the Sponsor.    
6 Serum creatinine will be measured as part of the clinical laboratory assessment . 
7 12-lead ECG at Screening, Day 1 pre- dose, and prior to discharge from clinic on Day 8.  Electrocardiograms to be obtained following 5 minutes rest in supine 
or semi -recumbent  position.  The same position must be used throughout the study for a given subject.   
8 Vital signs will be measured following 5 minutes rest in a seated position .  Systolic and diastolic blood pressure, pulse rate, respiratory rate, body temperature  
will be measured at the following time points: prior to Day -1 procedures, prior to discharge from CRU  on Day 8, and at the E nd of Study visit.  In addition, 
blood pressur e and pulse rate  will also be measured before each administration of study medication in the CRU .  
9 Complete physical examination at Screening, and prior to discharge on Day 8 .  Brief physical examination on Day - 2 or Day - 1.  Symptom -directed physical 
examinations as needed. 
10 Adverse events and SAEs that are related to study participation (e.g., protocol -mandated intervention) will be recorded from the time the subject  signs the 
informed consent form until exit from the study.  All other AEs and SAEs will be recorded from the first dose of lixivaptan until exit from the study.  
11 Record daily fluid intake on Day - 1, Day 1 and Day 7.  On Day - 1, measurement will begin 24  hours before the expected time of first study medication on Day 
1 AM.  On Day 1 and Day 7, measurements will begin immediately before the AM dose and will continue for 24 hours into the morning  of Day 2 and Day 8, 
respectively.      
12 Subject s will take study medication in the AM and PM for 7 days.   Subject s will be asked to record each dose of the study product taken on an outpatient basis 
in the Study Dosing Diary.  Subjects will be asked to bring the Study Dosing Diary together with their unused study product at each visit to the CRU.  
13 PK blood collection timepoints:  
Day 1 : 0, 1, 2, 4, 6, 9, 10 , 11, 12, 14, and 16 hours  post AM dose . The collections at 0 and 10 hours are immediately before the AM and PM dose s, respectively;  
Day 2 , 4 and 6: 0 hours  (immediately before AM dose ); 
Day 7 : 0, 1, 2, 4, 6, 9, 10, 11, 12, 14, and 16 hours  post AM dose . The collections at 0 and 10  hours are immediately before the AM and PM doses , respectively ; 
Day 8 : 0 hours ( corresponding to 24 hours after AM dose on Day 7 ) and 10 hours ( corresponding to 24 hours after PM dose  on Day 7 );  
Day 9 : 48 hours af ter PM dose on Day 7 ;  
Day 1 1: 96 hours  after PM dose on Day 7 .  
14 Urine will be collected for determination of spot urine osmolality and  urine specific gravity at the following timepoints:  
Day -1: 0 (start), 1, 2, 4, 6, 9, 10, 11, 12, and 14 hours . 
Palladio Biosciences PA -102 Page 65 of 66 
 
21-Mar-2019 Confidential Information  Version 5  Day 1: 0 , 1, 2, 4, 6, 9, 10, 11, 12, and 14 hours  post AM dose . The colle ctions at 0 and 10 hours are immediately before the AM and PM doses , respectively;  
Day 2: 0 hours  (immediately before AM dose on Day 2 , corresponding to 24 hours after AM dose on Day 1). 
Day 7 : 0, 1, 2, 4, 6, 9, 10, 11, 12, and 14 hours  post AM dose . The collections at 0 and 10  hours are immediately before the AM and PM doses , respectively ; 
Day 8: 0 hours  (corresponding to 24 hours after AM dose on Day 7). 
Note: Subject may not be able to void at all timepoints  - see Section 6.1.7 .  For all voids, the volume (mL) and the date and time of void w ill be record ed.   
15 Record d aily urine output on Day -1, Day 1 and Day 7.   On Day -1, measurement will begin 24 hours before the expected time of first study medication on 
Day 1 AM.  On Day 1 and Day 7, measurements will begin immediately before the AM dose and will continue for 24 hours into the  morning of Day 2 and Day 
8, respectively.       
16 Blood samples for determination of plasma copeptin will be taken at approximately the same time of day (in the morning and , on dosing days, before the 
lixivaptan dose).  
17 Subjects will be admitted to the CRU in the evening of Day -2 or in the morning of Day -1.  For subjects admitted to the CRU on Day -2, the Screening period 
will be until Day -3.  For subjects admitted to the CRU on Day - 1, the Screening period will be unt il Day -2.   
18 Three PK sampling points are contemplated after patients are discharged from the CRU on Day 8 (Day 8 PM, Day 9 PM, Day 11 PM) .  Patients may return to 
the site for the se PK sample collection s.  Alternatively, if patient s are not able to ret urn to the CRU  after discharge, they may utilize a n at-home nursing service 
provided by the Sponsor.  If a patient does not return to the site for PK sample collection after discharge on Day 8 , but has the blood drawn by an at -home 
nursing service, this wi ll not be considered a protocol deviation.  
 
 
Palladio Biosciences  PA-102 Page 66 of 66 
 
 21-Mar-2019 Confidential Information  Version 5  12.3 Appendix  3: Assessment Windows 
Table 12-2 Assessment Windows  
Procedure  Dosing Day  Window (units)  
Lixivaptan PM dose  Day 1 – Day 7  In CRU: 10 hr ± 15 minutes  after AM dose  
Self-Administered: 10 hr ±  1 hr after AM dose  
   
 Assessment Day   
PK Blood S amples  Day 1, Day 2, Day 4, Day 
6, Day 7, Day 8, Day 9 , 
Day 11  - 60 minutes (predose  Day 1 ) 
- 10 minutes (predose  Day 7)  
± 3 min  (≤4 hr)  
± 5 min  (> 4 hr but ≤ 12 hr)  
± 10 min  (> 12 hr but ≤ 24 hr)  
 
± 1 hr (> 24 hr but ≤ 48 hr)  
± 2 hr (> 48) 
Urine Osmolality  and  
Urine Specific Gravity  Day 1-2, Day 7 -8 Subjects will empty their bladders completely 15 
± 5 minutes prior to each scheduled collection, 
after which they will have 30 minutes to provide 
a spot urine s ample .  Subjects who will not be 
able to provide a sample within 30 minutes will 
be given an additional 30 minutes to do so and 
the different sampling time will be recorded.   
Electrocardiogram  Screening, Day 1, Day 8  - 60 minutes (predose ), ± 30 minutes (postdose ) 
Vital Signs Screening, Day - 1, Day 1, 
Day 2, Day 4, Day 6, Day 
7, Day 8, Day 35 - 60 minutes (predose ), ± 30 minutes (postdose ) 
Clinical Laboratory 
Samples  Screening, Day - 1, Day 2, 
Day 7, Day 35  - 60 minutes (predose  Day 2 and Day 7 ) 
In the morning o n Day - 1 and Day 35 
Tolerability Questionnaire  Day 2, Day 7  Subjects will complete the questionnaire in the 
morning of Day  2, before discharge from the 
CRU, and in the morning of Day 7.  
TKV and LV (MRI)  Baseline  
End of dosing 
End of study Baseline: between Screening and Day -1  
End of dosing: Day 7 or 8 or 9  
End of study: Day 35  ± 2  
Table abbreviations: hr = hours, PK= pharmacokinetic  
 
Summary of Changes in the Conduct of the Study (from Section 9.8.1 of the Clinical S tudy 
Report, dated September 22, 2020  
 
Changes in the Conduct of the Study  
There were 2 protocol versions that were not implemented or submitted to the IRB. Protocol  
versions 1 and 2 were marked final and dated 19 March 2018 but the version number 1.0  
remained unchanged in the footer of both ve rsions. Refer to Note to File (dated 23 February  
2020) in Appendix 16.1.1 to distinguish between the 2 documents.  
Protocol version 3 (dated 24 April 2018) was the first protocol version submitted to the IRBs  and 
amended. There were 2 subsequent protocol am endments, versions 4 and 5, that were  
implemented after the first subject was enrolled. Copies of the protocol and protocol  
amendments are provided in Appendix 16.1.1. Brief summaries of the changes are outlined  
below.  
Protocol version 4 (dated 09 January 2019) implemented the following changes:  
• Clinically relevant changes that affected the type or frequency of protocol procedures, or  
the addition of information to the protocol that influenced clinical decision making or  
consent:  
− Increased eligible age t o 65 years for inclusion in the study;  
− Provided flexibility in screening procedures;  
− Allowed the use of the low progesterone -releasing intrauterine device Mirena;  
− Limited hormonal contraception exclusion to estrogen -containing contraceptives.  
Progesterone -only contraceptives were allowed.  
− Allowed inclusion of subjects with elevated bilirubin due to Gilbert’s Syndrome  
at the discretion of the investigator.  
− Allowed inclusion of subjects with contraindications to or interference with MRI  
asses sments provided they met all other inclusion criteria. Clarified that no MRI  
tests would be conducted on these subjects.  
− Added exclusion of subjects who showed signs of liver toxicity on tolvaptan  
therapy.  
− Clarified batch number of investigational prod uct. 
− Clarified fluid intake recommendations before the first dose of study drug and  
while taking study drug.  
− Allowed supine position for ECGs provided that the same position was  
maintained for the same subject throughout the study.  
− Clarified nature o f pregnancy test at EOS visit.  
− Added Day 11 to the Assessment Window table.  
− Clarified the appropriate time window for time values that were on the extremes  
of each time interval.  
• Clarified text which included corrections of typos, text changes for co nsistency or other  
clarifications which did not affect clinical decision making or consent. These included  
deletion of mesylate, the counter -ion of fenoldopam from the exclusion criteria.  
• Administrative changes, including changes of names or roles of com panies or personnel  
and/or contact information. These changes did not affect clinical decision making or  
consent.  
 
Protocol version 5 (dated 21 March 2019) implemented the following changes:  
• Clinically relevant changes that affected the type or frequency of protocol procedures, or  
the addition of information to the protocol that influenced clinical decision making or  
consent:  
− Extended screening duration from 4 weeks to 6 weeks.  
− Increased study duration by the addition of 14 days to Screening.  
− Updated information on the status of the vasopressin V 2 receptor antagonist  
tolvaptan (JYNARQUE®) in the US.  
− Provided flexibility to stop enrollment of CKD1 subjects in Cohorts 1 and 3 if  
sufficient experience with CKD2 subjects had not occurred.  
− Provided the use of a home nursing service to draw blood if repeat lab tests were  
needed during Screening.  
− Deleted amlodipine from the exclusion criteria and prohibited therapy as it was a  
CYP3A4 substrate and not an inhibitor.  
− As inhibition of CYP3A4 by lixivaptan might reduce metabolism of amlodipine, a  
dosing limit was added.  
− Increased the allowable upper limit of liver function test (LFT) results at  
Screening to 1.5 × ULN based on th e observation in the first 8 subjects treated  
with lixivaptan at 200 mg BID (highest dose) in this study that no significant LFT  
abnormalities had been detected. The highest values were 1.2 × ULN for  
transaminases with no increase in total bilirubin.  
− Clarified that if a subject did not come back for visits after Day 8, it was not a  
protocol deviation if the blood was drawn only by the at -home nursing service.  
• Clarified text which included corrections of typos, text changes for consistency or other  
clarifications. These changes did not affect clinical decision making or consent.  
• Administrative changes, including changes of names or roles of companies or personnel  
and/or contact information. These changes did not affect clinical decision making or  
consen t. 
Palladio Biosciences      Summary of Changes  
Study PA -102     Clinical Study Protocol version 5 dated March 21, 2019  
Confidential   1 S
tudy PA -102 
Clinical Study Protocol version 5 dated March 21, 2019 
Summary of Changes  
T
his Summary of Changes document should be used in conjunction with the track ed-changes version of the clinical study protocol 
amendment .  Page numbers reported herein refer to the tracked- changes version.
Ad
ministrative Changes  
This section lists administrative changes, including changes of names or roles of companies or personnel and/or contact information. No 
changes listed here affect clinical decision making or consent.  
Page Section  Version 4 dated January 9, 2019 Version 5 Explanation  
1 Title page  Version of Protocol: 4 Version of Protocol: 5 Clarifies protocol version  
1 Title page  Date of protocol: January 9, 2019  Date of protocol: March 21, 2019 Updates protocol date  
1 Title page  Sponsor Contact:  
Ruth Ann Subach, PharmD, BCPS  
Vice President, Clinical 
Development and Operations  
Design Space Inpharmatics, LLC  
Harleysville, PA 19438  
rsubach@dsipharmatics.com  Sponsor Contact : 
Elaine Richardson  
Vice President, Clinical Operations  
Palladio Biosciences, Inc.  
12 Penns Trail, Unit A  
Newtown, PA 18940  
ERichardson@palladiobio.com  Updates Sponsor Contact  
name and contact 
information.  
3 Protocol approval  – 
Sponsor signature  Version of Protocol: 4 Version of Protocol: 5 Updates  protocol version  
Palladio Biosciences          Summary of Changes  
Study PA -102                                                                                    Clinical Study Protocol version 5 dated March 21, 2019  
Confidential                                        2 
 Page Section  Version 4 dated January 9, 2019 Version 5 Explanation  
3 Protocol approval –  
Sponsor signature  Protocol date January 9, 2019 Protocol date March 21, 2019 Updates protocol date  
3 Protocol approval –  
Sponsor signature  Lorenzo Pellegrini, Ph.D.  
President & CEO  
Palladio Biosciences, Inc.  
12 Penns Trail, Unit A  
Newtown, PA 18940  Neil H. Shusterman, M.D.  
Chief Medical Officer  
Palladio Biosciences, Inc.  
12 Penns Trail, Unit A  
Newtown, PA 18940 Change of responsibility to 
Chief Medical Officer  
3 Protocol approval –  
Sponsor signature  Signature date January 9, 2019  Signature date March 21, 2019  Updates protocol date  
11 Synopsis  Date of protocol: January 9, 2019  Date of protocol: March 21, 2019  Updates protocol date  
All Footnote  09-Jan-2019  21-Mar-2019  Updates protocol date  
All Footnote  Version 4  Version 5  Updates  protocol version  
 
  
Palladio Biosciences          Summary of Changes  
Study PA -102                                                                                    Clinical Study Protocol version 5 dated March 21, 2019  
Confidential                                        3 
  
Text Clarifications  
This section lists corrections of typos, text chang es for consistency or other clarifications . These changes do not affect clinical decision 
making or consent.  
Page Section  Version 4 dated January 9, 2019 Version 5 Explanation  
11 Synopsis  Pharmacokinetic:  Lixivaptan and lixivaptan 
metabolite (WAY -141624, WAY -138451, and 
WAY- 138758) plasma concentrations will be 
tabulated and summarized using descriptive 
statistics (including sample size, arithmetic 
and geometric mean, standard deviation [SD], coefficient o f variation [CV%], median, 
minimum, and maximum) for each Cohort.  
The PK parameters for lixivaptan and 
lixivaptan metabolites will be will be  
summarized for each Cohort.  
 Pharmacokinetic:  Lixivaptan and lixivaptan 
metabolite (WAY -141624, WAY -138451, and 
WAY-138758) plasma concentrations will be 
tabulated and summarized using descriptive 
statistics (including sample size, arithmetic 
and geometric mean, standard deviation [SD], 
coefficient of variation [CV%], median, 
minimum, and maximum) for each Cohort.  
The PK parameters for lixivaptan and 
lixivaptan metabolites will be  summarized for 
each Cohort.  
 Delet ion of 
duplicate words  
13 List of 
Abbreviations   REMS Risk Evaluation and Mitigation Strategy  Adds new abbreviation 
35 5.8.1 Permitted 
Therapy  Allowed medications include those typically 
prescribed to treat ADPKD, CKD and their 
complications, with the exception of tolvaptan.  
These include angiotensin II receptor blockers 
(valsartan, candesartan, telmisartan, 
irbesartan) and angiotensin- converting 
enzyme inhibitors (enalapril, lisinopril).   Allowed medications include those typically 
prescribed to treat ADPKD, CKD and their 
complications, with the exception of tolvaptan.  
These include angiotensin II receptor blockers 
(e.g., valsartan, candesartan, telmisartan, 
irbesartan) and angiotensin- converting 
enzyme inhibitors ( e.g., enalapril, lisinopril).   Added “e.g.”, to 
show these are 
examples and 
not a complete 
list. 
  
Palladio Biosciences          Summary of Changes  
Study PA -102                                                                                    Clinical Study Protocol version 5 dated March 21, 2019  
Confidential                                        4 
  
Clinically -relevant Changes  
This section describes changes that affect the type or frequency of protocol procedures, or the addition of information to the protocol that 
influences clinical decision making or consent.  
 
Page Section  Version 4 dated January 9, 2019 Version 5 Comment s 
10 Synopsis  Screening Duration: 28 days (Day - 30 
through Day - 3)  Screening Duration: 42 days (Day - 44 
through Day - 3)  Extends the duration of 
Screening from 4 weeks to 6 
weeks  
10 Synopsis  Total Study Duration: 66 days  Total Study Duration: Up to 80 days  Study duration is increased 
by the addition of 14 days to 
Screening.  
16 1.3 Overview 
of Available 
Therapies for 
ADPKD  As of the time of this document there 
are no drug therapies specifically 
approved in the US for the treatment of 
ADPKD.  In April 2018, the vasopressin V 2 
receptor antagonist tolvaptan 
(JYNARQUE®) was approved in the 
US to slow kidney function decline in 
adults at risk of rapidly progressing 
ADPKD.  However, because of the 
risk of serious liver injury, Jynarque 
is only available through a restricted 
distribution program under a Risk 
Evaluation and Mitigation Strategy 
(REMS).  Updates information on the 
status of Jynarque in the 
United States.  
22 3.1 Study 
Design  For all subjects, this study includes a Screening period of 28 days (Day - 30 
through Day - 3), i.e. up to 30 days prior 
to dosing on Day 1.   For all subjects, this study includes a 
Screening period of 42 days (Day - 44 
through Day - 3), i.e. up to 44 days pr ior 
to dosing on Day 1.  Extends the duration of Screening from 4 weeks to 6 
weeks .  
Palladio Biosciences          Summary of Changes  
Study PA -102                                                                                    Clinical Study Protocol version 5 dated March 21, 2019  
Confidential                                        5 
 Page Section  Version 4 dated January 9, 2019 Version 5 Comment s 
23 3.1 Study 
Design , Table 
3-1, footnote  Table 3-1 Chronic Kidney Disease 
Classification Summary  
CKD 
Classification  Cohorts  N eGFR*  
    
CKD1 or 
CKD2** 1 and 3  16 (8 
per 
cohort)  eGFR ≥ 60 
mL/min/1.73 
m2 
    
CKD3  2 and 4  16 (8 
per 
cohort)  eGFR ≥ 30 
to < 60 
mL/min/1.73 
m2 
    
Abbreviations: CKD = chronic kidney disease, 
eGFR = estimated glomerular filtration rate, 
N = number  of subjects.  
*eGFR is calc ulated by the 2009 Chronic Kidney 
Disease Epidemiology Collaboration (CKD -EPI) 
equation ( Appendix 1 ).  
 Table 3-2 Chronic Kidney Disease 
Classification Summary  
CKD 
Classification  Cohorts  N eGFR*  
    
CKD1 or 
CKD2 ** 1 and 3  16 (8 
per 
cohort)  eGFR ≥ 60 
mL/min/1.73 
m2 
    
CKD3  2 and 4  16 (8 
per 
cohort)  eGFR ≥ 30 
to < 60 
mL/min/1.73 
m2 
    
Abbreviations: CKD = chronic kidney disease, 
eGFR = estimated glomerular filtration rate, 
N = number  of subjects.  
*eGFR is calc ulated by the 2009 Chronic Kidney 
Disease Epidemiology Collaboration (CKD -EPI) 
equation ( Appendix 1 ).  
**At least 2 subjects with CKD1 or CKD2 will 
be included in 8 subjects assigned to  Cohorts 
1 and 3 . Provides for  flexibility to stop 
enrollment of CKD1 subjects 
in Cohorts 1 and 3 if sufficient 
experience with CKD2 
subjects has not occurred.  
23 3.1 Study 
Design  Subjects may be allowed to re -screen or 
have repeat testing after agreement 
between the investigator and medical 
monitor.   Subjects may be allowed to re -screen or 
have repeat testing after agreement 
between the investigator and medical 
monitor.  Lab tests  that need to be 
repeated during Screening may be obtained through the services of an 
at-home nursing service provided by 
the Sponsor.  Provides for the use of a 
home nursing service to draw 
blood if repeat lab tests are 
needed during Screening.  
27 4.1.2 =  
Exclusion 
criteria  6.Subjects who have taken, or are 
expected to be taking, strong or 
moderate CYP3A4 or CYP2C8 inhibitors 
(e.g. aprepitant, boceprevir, 
clarithromycin, chloramphenicol (not eye 6.Subjects who have taken, or are 
expected to be taking, strong or 
moderate CYP3A4 or CYP2C8 inhibitors 
(e.g. aprepitant, boceprevir, 
clarithromycin, chloramphenicol (not eye Amlodipine is a CYP3A4 
substrate and not an inhibitor.  
Thus , it has been deleted 
from this section.  
Palladio Biosciences          Summary of Changes  
Study PA -102                                                                                    Clinical Study Protocol version 5 dated March 21, 2019  
Confidential                                        6 
 Page Section  Version 4 dated January 9, 2019 Version 5 Comment s 
drops), cimetidine, ciprofloxacin, 
clopidogrel, clotrimazole (if used orally), 
cobicistat and cobicistat -containing 
products, crizotinib, cyclosporine, danazol, deferasirox, diltiazem, 
dronedarone, erythromycin, fluconazole, 
fluvoxamine, gemfibrozil, HIV p rotease 
inhibitors, imatinib, isoniazid, itraconazole, josamycin, ketoconazole, 
nefazodone, posaconazole, 
quinupristin/dalfopristin, ritonavir and 
ritonavir -containing products, telaprevir, 
teriflunomide, tofisopam, troleandomycin, verapamil, 
voriconazole)  within 14 days or 5 half -
lives, whichever is longer, of dosing;  or 
weak CYP3A4 or CYP2C8 inhibitors 
(e.g., amlodipine, chlorzoxazone, 
cilostazol, fosaprepitant, istradefylline, 
ivacaftor, lomitapide, ranitidine, 
ranolazine, tacrolimus, ticagrelor, 
trimet hoprim ) within 7 days or 5 half -
lives, whichever is longer, from dosing.  
For weak CYP3A4 or CYP2C8  
inhibitors, medications may be allowed in consultation with the Medical Monitor 
(MM).  drops), cimetidine, ciprofloxacin, 
clopidogrel, clotrimazole (if used orally), 
cobicistat and cobicistat -containing 
products, crizotinib, cyclosporine, danazol, deferasirox, diltiazem, 
dronedarone, erythromycin, fluconazole, 
fluvoxamine, gemfibrozil, HIV protease 
inhibitors, imatinib, isoniazid, 
itraconazole, josamycin, ketoconazole, 
nefazodone, posaconazole, 
quinupristin/dalfopristin, ritonavir and 
ritonavir -containing products, telaprevir, 
teriflunomide, tofisopam, troleandomycin, verapamil, 
voriconazole) within 14 days or 5 half -
lives, whichever is longer, of dosing;  or 
weak CYP3A4 or  CYP2C8 inhibitors 
(e.g., amlodipine, chlorzoxazone, 
cilostazol, fosaprepitant, istradefylline, ivacaftor, lomitapide, ranitidine, 
ranolazine, tacrolimus, ticagrelor, 
trimethoprim ) within 7 days or 5 half -
lives, whichever is longer, from dosing.  
For weak CYP3A4 or CYP2C8  
inhibitors, medications may be allowed 
in consultation with the Medical Monitor 
(MM).  
28 4.1.2. – 
Exclusion 
criteria  15.  Subjects with aspartate 
aminotransferase (AST), alanine aminotransferase (ALT), gamma -
glutamyltransferase (GGT), alkaline phosphatase (ALP) or total bilirubin ≥ 
1.0 × upper limit of normal (ULN) at 
Screening.  Subjects with elevated 15.  Subjects with aspartate 
aminotransferase (AST), alanine 
aminotransferase (ALT), gamma -
glutamyltransferase (GGT), alkaline phosphatase (ALP) or total bilirubin >  
1.5 × upper limit of normal (ULN) at 
Screening.  Subjects with elevated Increases the allowable 
upper limit of liver function 
test (LFT) results at 
Screening to 1.5 ×  the upper 
limit of normal based on t he 
observation in the first 8 
subjects treated with 
Palladio Biosciences          Summary of Changes  
Study PA -102                                                                                    Clinical Study Protocol version 5 dated March 21, 2019  
Confidential                                        7 
 Page Section  Version 4 dated January 9, 2019 Version 5 Comment s 
bilirubin due to Gilbert’s Syndrome m ay 
be allowed at the discretion of the 
Investigator.  bilirubin due to Gilbert’s Syndrome may 
be allowed at the discretion of the Investigator.  lixivaptan at 200 mg BID 
(highest dose) in this study that no significant LFT 
abnormalities have been 
detected. The highest values 
were 1.2 times the upper limit 
of normal  for transaminases 
with no increa se in total 
bilirubin . 
32 5.2 Blinding 
and 
Randomization  This is an open -label study and no 
blinding procedures will be used.  Following enrollment, subjects will be 
centrally assigned to one of 4 cohorts 
depending on CKD status (Table 5 1) 
and based on a predetermined 
algorithm.  The 200 mg BID dose 
cohorts will be enrolled first.  At least 2 
males or females will be included in the 
8 subjects (i.e., can be up to a 25%/75% 
split of male/female or 75%/25% split of 
male/female) assigned to each cohort.  This is an open -label study and no 
blinding procedures will be used.  
Following enrollment, subjects will be 
centrally assigned to one of 4 cohorts 
depending on CKD status (Table 5 1) 
and based on a predetermined 
algorithm.  The 200 mg BID dose 
cohorts wil l be enrolled first.  At least 2 
males or females will be included in the 
8 subjects (i.e., can be up to a 25%/75% split of male/female or 75%/25% split of 
male/female) assigned to each cohort. 
Similarly, at least 2 subjects with 
CKD1 or CKD2 will be included in 8 
subjects each assigned to  Cohorts 1 
and 3.  Provides for flexibility to stop 
enrollment of CKD1 subjects 
in Cohorts 1 and 3 if sufficient 
experience with CKD2 
subjects has not occurred.  
36 5.8.1 – 
Permitted 
therapy  Lixivaptan has the potential to inhibit the 
metabolism of CYP3A4 and CYP2C8 
substrates, including atorvastatin and 
simvastatin, therefore care should be 
exercised when administering lixivaptan 
in combination with these substrates.  In 
order to minimize the potential for AEs Lixivaptan has the potential to inhibit the metabolism of CYP3A4 and CYP2C8 
substrates, including atorvastatin, and 
simvastatin, and amlodipine.  
Therefore, care should be exercised 
when administering lixivaptan in 
combination with these substrates.  In Because inhibition of 
CYP3A4 by lixivaptan may 
reduce metabolism of 
amlodipine, a dosing limit has 
been added.  
Palladio Biosciences          Summary of Changes  
Study PA -102                                                                                    Clinical Study Protocol version 5 dated March 21, 2019  
Confidential                                        8 
 Page Section  Version 4 dated January 9, 2019 Version 5 Comment s 
due to drug -drug interactions, prior to 
enrollment in the study, the Investigator, 
in consultation with the Medical Monitor, 
should consider potential dose 
adjustments or alternative therapeutic 
options that are not CYP3A4 or 
CYP2C8 substrates (e.g. rosuvastatin to 
replace simvastatin or atorvastatin) or 
that have a high therapeutic index.  If 
subjects are receiving simvastatin as 
background medication and it is not 
possible to replace simvastatin with 
rosuvastatin, the dose of simvastatin 
should be decreased to < 20 mg daily in 
subjects who are administered the 50 mg BID dose of lixivaptan and < 10 mg 
daily in subjects who are administered 
the 200 mg BID dose of lixivaptan.  order to minimize the potential for AEs 
due to drug- drug interactions, prior to 
enrollment in the study, the Investigator, 
in consultation with the Medical Monitor, 
should consider potential dose 
adjustments or alternative therapeutic 
options that are not CYP 3A4 or 
CYP2C8 substrates (e.g. rosuvastatin to replace simvastatin or atorvastatin) or 
that have a high therapeutic index.  If 
subjects are receiving simvastatin as 
background medication and it is not 
possible to replace simvastatin with 
rosuvastatin, the dose of simvastatin 
should be decreased to < 20 mg daily in 
subjects who are administered the 50 
mg BID dose of lixivaptan and < 10 mg 
daily in subjects who are administered 
the 200 mg BID dose of lixivaptan.  If 
amlodipine is needed for clinical 
care, the dose should not exceed 5 
mg daily.  
37 5.8.2 
Prohibited 
Therapy  • Treatment with weak CYP3A4 or 
CYP2C8  inhibitors, including  
amlodipine, chlorzoxazone, 
cilostazol, fosaprepitant, 
istradefylline, ivacaftor, lomitapide, 
ranitidine, ranolazine, tacrolimus, 
ticagrelor, trimethoprim.  For weak 
CYP3A4 or CYP2C8  inhibitors, 
medications may be allowed in 
consultation with the Medical 
Monitor;  • Treatment with weak CYP3A4 or 
CYP2C8  inhibitors, including  
amlodipine,  chlorzoxazone, 
cilostazol, fosaprepitant, 
istradefylline, ivacaftor, lomitapide, 
ranitidine, ranolazine, tacrolimus, 
ticagrelor, trimethoprim.  For weak 
CYP3A4 or CYP2C8  inhibitors, 
medicat ions may be allowed in 
consultation with the Medical 
Monitor;  Amlodipine is a CYP3A4 
substrate and not an inhibitor.  
Thus, it has been deleted from this section.  
Palladio Biosciences          Summary of Changes  
Study PA -102                                                                                    Clinical Study Protocol version 5 dated March 21, 2019  
Confidential                                        9 
 Page Section  Version 4 dated January 9, 2019 Version 5 Comment s 
  
63 Table 21 -1 
Schedule of 
Assessments  Screening 
-30 to - 3 or -2 Screening -44 to -3 or -2 Increased duration of 
Screening from 4 weeks to 6 
weeks  
64 Footnote 5 to Table 12 -1 - 
Schedule of Assessments  5. Clinical labs: hematology, clinical 
chemistry (including liver function), and 
urinalysis at approximately the same 
time of day (in the morning and, on 
dosing days, before the lixivaptan dose).  
The list of analytes is shown in Table 
6-1.  . 5. Clinical labs: hematology, clinical 
chemistry (including liver function), and 
urinalysis at approximately the same 
time of day (in the morning and, on 
dosing days , before the lixivaptan dose).  
The list of analytes is shown in Table 
6-1. Lab tests that need to be 
repeated during Screening may be 
obtained through the services of an 
at-home nursing service provided by 
the Sponsor.   Provides for the use of a 
home nursing service to draw 
blood if repeat lab tests are 
needed during Screening.  
65 Footnote 18 to 
Table 12 -1 - 
Schedule of Assessments  If a patient does not return to the site for PK sample collection after discharge on 
Day 8, this will not be considered a 
protocol deviation.  If a patient does not return to the site for PK sample collection after discharge on 
Day 8, but has the blood drawn by an 
at-home nursing service,  this will not 
be considered a protocol deviation.  Indicates that if a subject does not come back for visits 
after Day 8, then it is not a 
protocol deviation only  if the 
blood is drawn by the at -
home nursing service.  
 
Palladio Biosciences          Summary of Changes  
Study PA -102                                                                                    Clinical Study Protocol version 4 dated January 9 , 2019 
Confidential                                        1 
  
Study PA -102 
Clinical Study Protocol version 4 dated January 9, 2019 
Summary of Changes  
 
This Summary of Changes document should be used in conjunction with the track ed-changes version of the clinical study protocol 
amendment .  Page numbers reported herein refer to the tracked- changes version.   
 
Administrative Changes  
This section lists administrative changes, including changes of names or roles of companies or personnel and/or contact information. No 
changes listed here affect clinical decision making or consent.  
Page Section  Version 3 dated April 24, 2018  Version 4  Explanation  
1 Title page Version of Protocol: 3 Version of Protocol: 4  Clarifies protocol version  
1 Title page  Date of protocol: Apr il 24, 2018  Date of protocol: January 9, 2019 Updates protocol date  
1 Title page  Medical Monitor:   
Hooman Hajian, MD, MPH  
Medical Director, IQVIA  
10188 Telesis Court, Suite 400  
San Diego, CA  92121  
Mobile: (425) 205 0946  Medical Monitor:  
Andrew Lowy, MD, FRACP  
Medical Director, IQVIA  
Direct: (984) 201- 6550 (including 
urgent medical issues)  
Mobile: (310)  431- 7666  
Fax: +1 (520) 829- 9405  
Email: Andrew.Lowy@quintiles.com  
 
IQVIA 24/7 Medical Emergency 
Contact Center (MECC):  
(973) 659- 6677;  
(512) 652 -0191 (back -up) Updates Medical Monitor 
name and contact 
information.  Adds contact 
information for Medical 
Emergency Contact Center.  
Palladio Biosciences          Summary of Changes  
Study PA -102                                                                                    Clinical Study Protocol version 4 dated January 9 , 2019 
Confidential                                        2 
 Page Section  Version 3 dated April 24, 2018  Version 4  Explanation  
All Footnote  24-Apr-2018  09-Jan-2019  Updates protocol date  
All Footnote  Version 3 Version 4 Clarifies protocol version  
3 Protocol approval  – 
Sponsor signature  Version of Protocol: 3  Version of Protocol: 4  Clarifies protocol version  
3 Protocol approval – 
Sponsor signature  Protocol date April 24, 2018 Protocol date January 9, 2019  Updates protocol date  
3 Protocol approval – Sponsor signature  Signature date April 24, 2018 Signature date January 9, 2019  Updates protocol date  
4 Declaration of investigator  …the accompanying Investigator 
Brochure (IB), version 15, dated 
March 12, 2018 . …the accompanying current version of the Investigator Brochure (IB) . Updates version of 
Investigator Brochure by referring to the current version, which is 
documented in the trial master file. 
11 Synopsis  Date of protocol: April 24, 2018  Date of protocol: January 9, 2019 Updates protocol date  
28 4.1.2. – Exclusion 
criteria    Updated exclusion criteria 
numbering to reflect insertion of one additional exclusion 
criterion  at position 2 6 in the 
list 
 
  
Palladio Biosciences          Summary of Changes  
Study PA -102                                                                                    Clinical Study Protocol version 4 dated January 9 , 2019 
Confidential                                        3 
  
Text Clarifications 
This section lists corrections of typos, text chang es for consistency or other clarifications . These changes do not affect clinical decision 
making or consent.  
Page Section  Version 3 dated April 24, 2018  Version 4  Explanation  
26 4.1.2 – 
Exclusion 
criteria  1. Subjects with known sensitivity or 
idiosyncratic reaction to any compound present in lixivaptan, its related compounds such as benzazepines (e.g., tolvaptan, 
conivaptan, benazepril, fenoldopam , 
mesylate,  or mirtazapine), or any compound 
listed as being present in the study 
formulation.  1. Subjects with known sensitivity or 
idiosyncratic reaction to any compound present in lixivaptan, its related compounds such as benzazepines (e.g., tolvaptan, 
conivaptan, benazepril, fenoldopam, or 
mirtazapine), or any compound listed as being 
present in the study formulation.  Delet ion of 
mesylate , the 
counter -ion of 
fenoldopam  
27 4.1.2 – 
Exclusion 
criteria  18. Subjects have experienced an illness that 
is considered by the Investigator to be 
clinically significant within 2 weeks of study 
drug administration on Day 1.  19. Subjects who have experienced an illness 
that is considered by the Investigator to be 
clinically significant within 2 weeks of study 
drug administration on Day 1.   
39 6.1.6 – MRI 
Assessment Given the importance of performing the second MRI assessment within a short t ime 
interval after the last dose of study medication (PM dose on Day 7), all MRI assessments will 
be scheduled for each subject in conjunction with the Screening visit.   Given the importance of performing the 
second MRI assessment within a short time 
interval after the last dose of study medication 
(PM dose on Day 7), it is recommended that  
all MRI assessments be scheduled for each subject at the time of  the Screening visit.   
61 12 -
APPENDICES  This study uses the 2009 CKD -EPI creatinine 
equation,16 which is recommended by the 
KDIGO Clinical Practice Guidelines for Management of Chronic Kidney Disease
3. This study uses the 2009 CKD -EPI creatinine 
equation,16 which is recommended by the 
KDIGO Clinical Practice Guidelines for 
Manag ement of Chronic Kidney Disease. Deletion of reference at end 
of sentence.  
  
Palladio Biosciences          Summary of Changes  
Study PA -102                                                                                    Clinical Study Protocol version 4 dated January 9 , 2019 
Confidential                                        4 
  
Clinically-relevant Changes  
This section describes changes that affect the type or frequency of protocol procedures, or the addition of information to the protocol that influences clinical decision making or consent.  
 
Page Section  Version 3 dated April 24, 2018  Version 4  Comment s 
9 Synopsis  The subjects will be male or 
female, between 18 and 60 years 
of age. The subjects will be male or 
female, between 18 and 65 years 
of age. Increases the eligible age for 
inclusion into the study to 65 
years . 
22 3.1 - Study Design  Subjects will be allowed to re -
screen for the study for up to two 
times.  Subjects may be allowed to re-
screen or have repeat testing after agreement between the investigator and medical 
monitor.  Introduces more flexibility in screening procedures.  
24 4.1.1 – Inclusion 
Criteria  2.  Male or female, between 18 
and 60 years of age (inclusive) at 
the time of Screening.  2.  Male or female, between 18 
and 65 years of age (inclusive) at 
the time of Screening.  Increases the eligible age for 
inclusion into the study to 65 years .  
25 4.1.1 – Inclusion 
Criteria  Double barrier methods of non -
hormonal contraception are 
permitted in this study.  Acceptable 
forms of contraception include the 
following: 
• intrauterine device Double barrier methods of non -
hormonal contraception are 
permitted in this study.  Acceptable 
forms of contraception include the following: 
• intrauterine device, including Mirena®  Clarifies that use of the low 
progesterone- releasing intrauterine 
device Mirena is allowed .  
25 4.1.1 – Inclusion 
Criteria  Hormonal contraception is not permitted in this pharmacokinetic 
study due to the potential for Estrogen- based  hormonal 
contraception is not permitted in 
this pharmacokinetic study due to Limits hormonal contraception exclusion to estrogen- containing 
contraceptives.  P rogesterone -only 
Palladio Biosciences          Summary of Changes  
Study PA -102                                                                                    Clinical Study Protocol version 4 dated January 9 , 2019 
Confidential                                        5 
 Page Section  Version 3 dated April 24, 2018  Version 4  Comment s 
interaction with lixivaptan.   the potential for interaction with 
lixivaptan.   contraceptives are allowed.    
27 4.1.2. – Exclusion 
criteria  15.  Subjects with aspartate 
aminotransferase (AST), alanine 
aminotransferase (ALT), gamma -
glutamyltransferase (GGT), alkaline phosphatase (ALP) or total bilirubin ≥ 1.0 × upper limit of 
normal (ULN) at Screening.   15.  Subjects with aspartate 
aminotransferase (AST), alanine 
aminotransferase (ALT), gamma -
glutamyltransferase (GGT), alkaline phosphatase (ALP) or total bilirubin ≥ 1.0 × upper limit of 
normal (ULN) at Screening.  
Subjects with elevated bilirubin 
due to Gilbert’s Syndrome may 
be allowed at the discretion of 
the Investigator.  Allows inclusion of subjects with 
elevated bilirubin due to Gilbert's 
Syndrome at the discretion of the 
Investigator.  
27 4.1.2. – Exclusion 
criteria  17. Subjects with contraindications 
to or interference with MRI assessments (ferromagnetic metal 
prostheses, aneurysm clips, 
severe claustrophobia, or large 
abdominal/back tattoos.  Investigator should seek MRI 
safety guidance from local MRI 
facility).  18. Subjects with contraindications 
to or int erference with MRI 
assessments (ferromagnetic metal prostheses, aneurysm clips, 
severe claustrophobia, or large 
abdominal/back tattoos) will be excused from this procedure, 
but may participate in the study 
providing that all other eligibility 
criteria are met.   Investigator 
should seek MRI safety guidance from local MRI facility.  Allows inclusion of subjects with 
contraindications to or interference 
with MRI assessments  provided 
they meet all other inclusion 
criteria.  Clarifies that no MRI tests 
will be conducted on these subjects.  
28 4.1.2. – Exclusion 
criteria   26. Subjects who have 
experienced elevated AST or ALT (defined as ≥ 2.0 × ULN) while taking tolvaptan.  Adds  exclusion of subjects who 
have shown signs of liver toxicity 
on tolvaptan therapy.  
Palladio Biosciences          Summary of Changes  
Study PA -102                                                                                    Clinical Study Protocol version 4 dated January 9 , 2019 
Confidential                                        6 
 Page Section  Version 3 dated April 24, 2018  Version 4  Comment s 
32 5.4 – Identity of 
Investigational 
Product  Batch 17120A  Batch 17121A 1 Clarifies batch number of 
investigational product.  
37 5.9 - Diet, Fluid, 
and Activity Control  Due to the expected aquaretic 
effects of lixivaptan, subjects 
should be reminded to maintain 
adequate fluid intake and be mindful of their thirst status at each 
study visit.  Subjects should be 
instructed to replenish fluids with 
each void and aim to drink  4-5 
liters of fluid per day, or as needed 
to maintain adequate hydration.   During Day s -2 and - 1 of CRU 
confinement, subjects should 
continue consuming their usual 
amount of fluids .  Due to the 
expected aquaretic effects of 
lixivaptan,  subjects should be 
reminded to maintain adequate fluid intake and be mindful of their 
thirst status at each study visit  
starting with Day 1 of CRU 
confinement .  Subjects should be 
instructed to replenish fluids with each void and aim to drink 4- 5 
liters of fluid per day, or  as needed 
to maintain adequate hydration, 
while taking lixivaptan .   Clarifies fluid intake recommendations before the first 
dose of study drug and while 
taking study drug .  
39 6.1.4 - 12-Lead 
Electrocardiograms  Electrocardiograms will be 
obtained with t he subject 
remaining in a semi -recumbent 
position following 5 minutes of rest.     Electrocardiograms will be obtained with the subject 
remaining in a supine or  semi -
recumbent position following 5 minutes of rest.  All 
electrocardiograms throughout the study for a given subject 
should be measured in the same 
position, i.e. either all in a 
supine position or all in a semi -
recumbent position.    Allows supine position for 
electrocardiograms  provided that 
the same position is maintained for the same subject throughout the 
study.  
Palladio Biosciences          Summary of Changes  
Study PA -102                                                                                    Clinical Study Protocol version 4 dated January 9 , 2019 
Confidential                                        7 
 Page Section  Version 3 dated April 24, 2018  Version 4  Comment s 
40 6.1.6 – MRI 
Assessment  Occasionally, patients may be 
unable to continue into the 
study after completing their  
Screening visit and  baseline MRI 
assessment (for example, due to personal circumstances or for 
not meeting laboratory inclusion 
criteria).  These patients may 
subsequently qualify for the 
study and be rescreened at a 
later time.  In this case, their 
prior baseline MRI assessment 
may be used instead of 
obtaining a new baseline MRI 
scan; provided, however, that no 
more than 8 weeks have elapsed 
from the time of the initial MRI assessment until admission into 
the CRU.    Clarifies that the baseline MRI assessment completed by patients 
who subsequently screen fail or 
are otherwise unable to continue 
into the study is valid for a period 
of 8 weeks .  Patients who 
successfully rescreen must be 
admitted into the CRU within 8 weeks from the original MRI 
assessment date for such MRI to be considered valid.   
41 6.1.6 – MRI 
Assessment Subjects with ferro- magnetic 
prostheses, aneurysm clips, severe claustrophobia or other 
contraindications or exclusions 
interfering with MRI measurements will be excluded from study 
participation.  Subjects with ferro- magnetic 
prostheses, aneurysm clips, 
severe claustrophobia or other 
contraindications or exclusions 
interfering with MRI measurements will be excused from this 
procedure, but may participate 
in the study providing that all 
other eligibility criteria are met.  
Investigator should seek MRI safety guidance from the local 
MRI facility . Allows inclusion of subjects with 
contraindications to or interference 
with MRI assessments  provided 
they meet all other inclusion 
criteria.  Clarifies that no MRI tests will be conducted on these 
subjects.  
Palladio Biosciences          Summary of Changes  
Study PA -102                                                                                    Clinical Study Protocol version 4 dated January 9 , 2019 
Confidential                                        8 
 Page Section  Version 3 dated April 24, 2018  Version 4  Comment s 
62 Footnote 2 to 
Table 12 -1 - 
Schedule of Assessments 2. Serum pregnancy test to be 
performed at Screening; Urine 
pregnancy test to be performed at 
Day -2 or Day - 1. 2. Serum pregnancy test to be 
performed at Screening; Urine 
pregnancy test to be performed at 
Day -2 or Day - 1 and at End of 
Study . Clarifies nature of pregnancy test at End of Study visit.  
63 Footnote 7 to 
Table 12 -1 – 
Schedule of 
Assessments Electrocardiograms to be obtained following 5 minutes rest in semi -recumbent position.  Electrocardiograms to be obtained following 5 minutes rest in supine 
or semi -recumbent position. The 
same position must be used throughout the study for a given 
subject.  Allows supine position for electrocardiograms  provided that 
the same position is maintained for 
the same subject throughout the 
study.  
63 Table 12 -2 - 
Assessment Windows .  
PK Blood Samples 
– Assessment Day  Day 1, Day 2, Day 4, Day 6, Day  7, 
Day 8, Day 9 Day 1, Day 2, Day 4, Day 6, Day 7, Day 8, Day 9, Day 11 Adds Day 11 to the Assessment Window table.  
65 Table 12 -2 - 
Assessment 
Windows .  
PK Blood Samples – Window (units)  - 60 minutes (predose Day 1)  
- 10 minutes (predose Day 7)  
± 3 min (< 1- 4 hr) 
± 5 min (> 4- 12 hr)  
± 10 min (> 12- 24 hr)  
± 1 hr (> 24 -48 hr)  
± 2 hr (> 48 -96 hr)  - 60 minutes (predose Day 1)  
- 10 minutes (predose Day 7)  
± 3 min (≤ 4 hr)  
± 5 min (> 4 hr but ≤ 12 hr)  
± 10 min (> 12 hr but ≤ 24 hr)  
± 1 hr (> 24 hr  but ≤ 48 hr)  
± 2 hr (> 48)  Clarifies the appropriate time 
window for time values that lie on the extremes of each time interval.  
 
 